Modulation of the angiogenic potential in collagen matrices by immobilisation of heparin and loading with vascular endothelial growth factor by Yao, Chang
Modulation of the angiogenic potential in collagen matrices
by immobilisation of heparin and loading with
vascular endothelial growth factor
Von der Medizinischen Fakultät der Rheinisch-Westfälischen Technischen Hochschule
Aachen
zur Erlangung des akademischen Grades eines
Doktors der Medizin
genehmigte Dissertation
vorgelegt von
Chang Yao
aus
Nanjing (VR China)
Berichter: Herr Universitätsprofessor
Dr.med. Dr. univ. med. N. Pallua
Herr Universitätsprofessor
Dr. rer.nat. Dipl.-Biochem. J. Bernhagen
Tag der mündlichen Prüfung: 17. Juni 2003
Diese Dissertation ist auf den Internetseiten der Hochschulbibliothek online verfügbar
1Contents
1 Introduction   5
1.1 General introduction 5
1.1.1 Plastic surgery 5
1.1.2 Tissue engineering 6
1.1.3 Angiogenesis 6
1.2 Collagen as a biomaterial 7
1.2.1 Collagen matrices as tissue substitutes 7
1.2.2 Collagen matrices as biomaterials with enhanced angiogenic potential 11
1.3 Cross-linking of collagen matrices 12
1.3.1 Introduction 12
1.3.2 EDC/NHS as a cross-linking agent 13
1.4 Immobilization of heparin to collagen matrices 15
1.4.1 Structure and  functions of heparin 15
1.4.2 Immobilization of heparin to collagen matrices by using
 the cross-linking agent EDC/NHS  16
1.5      Angiogenic growth factors 18
1.5.1 Introduction 18
1.5.2 Vascular endothelial growth factor 19
1.6 Incorporation of VEGF into collagen matrices 19
1.6.1 Introduction 19
1.6.2 Physical binding of VEGF to heparin cross-linked collagen 20
1.7 Methods to evaluate the characteristics of modified collagen matrices 21
21.7.1 Evaluation of  immobilized heparin 21
1.7.2 Moisture uptake 21
1.7.3 Determination of the in vitro degradation degree 22
1.7.4 Determination of free amino groups 23
1.8 Evaluation of angiogenic potential of modified matrices 23
1.8.1 Chorioallantoic membrane assay 23
1.8.2 Animal experiments 24
1.9 Aim of the thesis 24
2  Materials and Methods 28
2.1 Collagen matrices 28
2.2 Modification procedures 28
2.3 Determination of immobilized heparin 29
2.4 In vitro degradation  30
2.5 Determination of free amino groups 31
2.6      Determination of the moisture uptake  31
2.7 Determination of the angiogenic potential with the
chorioallantoic membrane assay ( CAM ) 32
2.8 Evaluation of the angiogenic potential bydetermination
of hemoglobin content of explanted matrices after implantation
into rats for 15 days 34
 3 Results 37
3.1 Determination of heparin immobilisation 37
3.1.1 Search for optimized reaction conditions 37
33.1.2 Heparin immobilisation as a function of different EDC/NHS
to heparin ratios 39
3.1.3 Heparin immobilisation as a function of different heparin to
EDC/NHS ratios 41
3.2 In vitro degradation with collagenase 41
3.3 Determination of free amino groups 45
3.4 Determination of the moisture uptake 46
3.5 Correlation of heparin immobilisation and in vitro degradation percent 48
3.6 Angiogenic potential 50
3.6.1 Angiogenic potential  evaluated by chorioallantois membrane assay 50
3.6.1.1 Macroscopic evaluation with CAM  assay 50
3.6.1.2 Microscopic evaluation with CAM assay 52
3.6.1.3 Angiogenic effect of immobilized heparin as determined
 by the CAM assay 53
3.6.1.4 Angiogenic effect of EDC/NHS cross-linking as determined by
CAM assay 54
3.6.1.5 The angiogenic effect of loading VEGF to heparinized and
 non-heparinized collagen matrices as evaluated by the CAM assay 56
3.6.2 Angiogenic effect of VEGF loading as determined by the
hemoglobin content of explanted collagen matrices 59
4 Discussion 62
4.1 The mechanism of the modification of collagen matrices 63
4.2 Heparin immobilisation 65
4.2.1 Optimal conditions for cross-linking heparin 65
4.2.2 Methods to determine the amount of immobilised heparin 66
4.2.3 Immobilised heparin as a function of varying  EDC/NHS
to heparin and heparin to EDC/NHS ratios (w/w) 67
44.3 Evaluation of  cross-linking of collagen matrices 68
4.4 Moisture uptake 71
4.5 Evaluation of the angiogenic potential of modified collagen matrices 72
4.5.1 Angiogenic effects determined with the CAM assay 72
4.5.1.1 Angiogenic effect of cross-linking in collagen matrices 72
4.5.1.2 Angiogenic effect of immobilised heparin in collagen matrices 73
4.5.1.3 Angiogenic effect of loading VEGF to (non-)modified collagen matrices 74
4.5.2 Angiogenic effect as determined by subcutaneous implantation in rats 76
4.6 Conclusions 77
4.6.1 Characteristics of modified collagen matrices 77
4.6.2 Angiogenic potential 77
4.7 Future prospects 78
5 Summary 80
6 References 83
7 Abbreviations 94
8 Acknowledgements 95
9 Curriculum vitae 96
51 Introduction
1.1 General Introduction
1.1.1 Plastic surgery
The aim of plastic surgery is the restoration of form and function with resultant
improvement in patient's quality of life and esthetic outcome. Accordingly, two main
tasks of plastic surgery are: 1. to improve the quality of wound healing in the repairing
area of a tissue deficit. 2. to reduce as much as possible the destruction in the donor
area.
Wound healing is fundamental to surgery. As to plastic surgery, one of the main
objectives is to reduce the scar formation of healing which will influence bothfunctional
restoration and the esthetic outcome. At the same time, restoration with less or without
destruction still challenges plastic surgery. Projection indicates that the gap between
tissue supply and demand will even continue to widen in the future.
Naturally, the question arises whether a tissue substitute may be developed which can
not only replace the deficit tissues, but can also improve the wound healing
simultaneously was proposed to meet the above demands. Fortunately, the rapid
development of modern science and the new findings, in biological materials and
factors involved with cell development gave birth to the interdisciplinary field of
research termed "Tissue Engineering".
1.1.2 Tissue engineering
Major advances in surgery often come from a cooperation of fundamental and clinical
research. To solve the problem of a significant shortage of tissues and organs suitable
for clinical transplantation (Koshland, 1990), tissue engineering was developed for
providing alternative therapies which can maintain, restore or improve lost tissue
functions by developing biological artificial tissue substitutes (Langer and Vacanti,
1993).
6Tissue engineering is a relatively new and emerging interdisciplinary field that applies
the knowledge of bioengineering, life science and the clinical sciences for creating new
functional substitutes for damaged host tissues (Nerem, 1992; Patrik et al., 1999).
Thus, it has been proposed as a therapeutic approach to treat patients suffering from
the loss or failure of organs and tissues.
With the approach of tissue engineering, many human tissues were developed by
using various kinds of biomaterials (Mooney and Mikos, 1999), which includes the
replacement of skin, soft tissue (Hollander et al., 2001), hard tissues (Hutmacher et al.,
2001), blood vessel and heart valve (Sodian et al., 2000; Watanabe et al., 2001). As
for the ideal biomaterials which serve as a temporal scaffold in the body, they should
be biocompatible, biodegradable, highly porous with a large surface to volume ratio,
mechanically strong, and capable of being formed into desired shapes, which play a
positive role in manipulating host cell functions by secreting their own extracellular
matrix proteins to form gradually normal, completely natural tissue. Collagen as a
natural extracellular matrix component, meets all the demands above. Therefore, it is
not surprising that collagen is the most commonly used biomaterial in skin, connective
tissue, peripheral nerve, blood vessel tissue engineering (Doillon et al., 1994b; Friess,
1998; Sheridan and Tompkins, 1999).
After synthetic biomaterials being implanted, a critical question is how to supply the
cells which grow into the biomaterials with sufficient oxygen and nutrients to sustain
their survival, proliferation and allow for the integration of the developing tissue with
the surrounding tissue. A rapid and high level of vascularization in transplanted
matrices is essential in tissue engineering approaches to meet this challenge.
1.1.3 Tissue engineering and Angiogenesis
Tissues with a high cell density require a vascular network of arteries, veins and
capillaries for the delivery of nutrients to each cell. Thus, the development of efficient
methods for enhancing angiogenic effects of biomaterials is critical for a successful
outcome. Generally, three approaches may lead to this goal: 1. Incorporation of
angiogenic factors in biomaterials. 2. Seeding of endothelial cells (ECs) along with
other cell types in biomaterials (Park et al., 2002). 3. Prevascularization of matrices
prior to cell seeding.
7It should be kept in mind that some fundamental guidelines must be followed (Soker et
al., 2000): 1. The support matrix for biomaterials must be compatible with EC growth
and capillary formation. It should have a high degree of porosity to allow the
penetration of blood vessel into the implant. 2. Angiogenic growth factors should be
applied for enhancing positive effects. 3. The combination of EC seeding with insertion
of a constitutive source for angiogenic factor secretion could be advantageous. 4. The
angiogenic process in biomaterials should be controlled before a functional vascular
network can be obtained, which is important since it was reported that sustained
overproduction of VEGF may result in deformed, non-functional blood vessels
(Springer et al., 1998).
1.2 Collagen as a biomaterial
1.2.1 Collagen matrices as tissue substitutes
Among biological materials, collagen, particularly type 1 collagen, is a major
component of various connective tissues, such as duramater, fascia, intestine, tail
tendons, etc. The replacement of human tissues with biomaterials, results in the
improvement of the wound-healing process because of the presence of collagen.
Therefore, the application of collagen-derived products as biomaterials has
tremendous advantages in biomedicine because of these products' natural structure
as a biological support for cells and scaffold for tissue repair or regeneration, their
biodegradability that obviates removal of implants, and their biocompatibility. It is not
surprising that collagen has been used to design numerous biomaterials in plastic
surgery, such as wound dressings, artificial dermis, tissue engineered devices, and
injectable materials (Hutmacher et al., 2001; Sodian et al., 2000; Watanabe et al.,
2001; Yannas et al., 1982).
In order to understand the good safety profile of collagen as a biomaterial and its role
in wound healing, its structure should be discussed first. The name collagen is used as
a generic term to cover a wide range of protein molecules, which form supra-molecular
structures. 14 types of collagen have been identified to date (van der Rest et al.,
1990), the most abundant being type 1 collagen (van der Rest et al., 1990). Because
8of its abundance in nature (more than 90% of all fibrous protein is Type 1 collagen)
and its unique physical and biological properties, Type 1 collagen has been used
extensively to formulate medical devices.  Therefore I concentrate my depiction to
Type 1 collagen.
The primary structure of collagen is unique, showing a strong internal sequence
homology, which places glycine at every third amino acid portion, and has a high
content of proline and hydroproline which contributes to forcing each collagen subunit
into helical structure. The three subunits are arranged in the form of a triple helical
procollagen, similar to a triple stranded rope (tertiary structure) (Zeeman, 1998a). The
procollagen is then exported into the extracellular space to form the collagen
monomer, with short non-helical ends of 15 to 25 amino acid residues (N-and C-
terminal telopeptides). Cross-linking renders these fibers stable and provide them with
an adequate degree of tensile strength and visco-elasticity to perform their structural
role. Two types of natural cross-links in collagen can be distinguished and are based
on the aldehyde groups formed from (hydroxy)lysine residues in the telopeptides, by
enzymatic oxidation by lysy/oxidase, yielding allysin. The collagen may be further
modified to form intra- and intermolecular cross-links which are formed by an aldol
condensation reaction of two aldehyde groups, or by the reaction of the aldehyde
group with the  ε-amino group of a (hydroxy)lysine residue of an adjacent helix
respectively (Nimni, 1988). With the aid of cross-linking, collagen can form fibers, and
then macroscopic bundles used to form tissue.
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Figure 1 The molecular architecture of the fiber forming collagen.
9From the structure of collagen, we know that collagen, the primary constituent of the
extracellular matrix, essentially consists of amino acids. The amino acids in collagen
contain side-chain groups such as amines (NH2), carboxylic acids (COOH) and
hydroxyls (OH), which together with the amide bond of the protein polymer, are sites
for possible chemical reaction on collagen. At the most basic level, a collagen
molecule consists of three chains of polypeptides arranged in a trihelical configuration
ending in non-helical carboxyl and amino terminals, one at each end.
These non-helical ends, which can be enzymatically or chemically removed and can
also be masked by cross-linking which minimizes non-helical ends (Furthmayr and
Timpl, 1976), are believed to contribute most to its antigenicity. In addition, when
cleaving the peptides bonds of collagen with the enzymes secreted from cells,
collagen can be biodegraded. Therefore, biomaterials based on collagen may be
modified to have properties as: high tensile strength, low extensibility, fiber orientation.
Their porous structure further allows for cell migration and proliferation, inhibition of the
wound contraction and acceleration of wound repair (Chvapil, 1982; Doillon et al.,
1984; Furthmayr and Timpl, 1976; Yannas and Burke, 1980). It is therefore not
surprising that collagen based biomaterials have been widely applied for medical use
and have been produced in a variety of forms such as film, gel, powder and sponge
(Pachence, 1996).
Collagen sponges or matrices are reconstituted from pure collagen. After forming a
0.5-2% slurry and frozen, collagen is dehydrated either by lyophilization or by
extraction with organic solvents to form sponges. The formed sponge can then be
cross-linked to stabilize the three-dimensional meshwork. In scanning electron
microscopy, the pore size within the matrices surface of the sponge is uneven and
irregular, showing the continuity of the pores ranging in size from 10 to 40 µm (Lau &
Richter, unpublished results). The pore size is crucial for cell permeation (Gey et al.,
1974), promotion of wound healing (Nathan et al., 1974) and regeneration of tissues
(Holmes et al., 1975; Hutmacher et al., 2001). In contact with aqueous liquid, collagen
sponges bind large volumes of liquid, which has a beneficial effect on cell adhesion
and mobility (Salzman, 1971).
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The research on collagen matrices as a scaffold for tissue engineering may be
classified into 4 aspects:
1 Cell seeding experiments: various types of cells, such as HUVEC cells (Wissink
et al., 2000c), human menses cells (Nakatake et al., 2001), hepatocytes
(Glicklis et al., 2000), chondrocytes (Glicklis et al., 2000), fibroblasts (Doillon et
al., 1994a) have been seeded into collagen matrices for testing the ability of
functioning as a scaffold. Generally these cells grow and proliferate successfully
within collagen scaffolds. Furthermore, stem cells, such as mesenchymal stem
cells (Hori et al., 2002), have also been applied in order to differentiate into the
desired mature cells. Some gene transfected cells, such as bone
morphogenetic protein-2-expressing muscle-derived cells (Lee et al., 2001)
have been used in order to express desired proteins or growth factors favorable
to tissue regeneration.
2 Incorporating growth factor experiments: The application of growth factors to
biomaterials has become an important aspect of tissue engineering because it
allows modulation of cellular function and tissue formation at the affiliated site
(Lu et al., 2000). As for the biomaterials based on collagen sponge, they have
been applied as a sustained released vehicle for various kinds of growth
factors, including epidermal growth factor (EGF), basic fibroblast growth factor
(bFGF)(Fujisato et al., 1996), VEGF (Dellian et al., 1996).
3 Experiments focussing on incorporating bioactive molecules. Some bioactive
molecules (e.g. heparin, hyaluronic acids, glycosaminoglycans) may have
substantial effects on the cell growth and may also stabilise the activity of
growth factors. Therefore, they were also incorporated into the collagen
sponges and their effects were evaluated in vitro and in vivo (Park et al., 2002;
Pieper et al., 2000a; Wissink et al., 2001a; Wissink et al., 2000b).
4 Experiments directed towards the modification of structural characteristics of the
collagen matrices. The internal structure of the matrices may have effects on
tissue ingrowth and response. Some investigations are focussing on modifying
the porous structure, for instance by treating them with alkaline (Rocha et al.,
2002).
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As a result of the above mentioned investigations, a number of devices have been
developed to commercial products for wound healing or as an artificial skin (Gao et
al., 2002).
1.2.2 Collagen matrices as biomaterial with enhanced angiogenic
potential
Angiogenesis is a multi-step process in which new blood vessels grow from existing
vessels. The sequential steps required for angiogenesis are extracellular matrix
remodeling, endothelial cell migration and proliferation, and capillary differentiation and
anastomosis (Ribatti et al., 1997).
A large number of angiogenic factors have been identified to be involved in the
development of new  vessels in a variety of assays. Angiogenesis plays a pivotal role
in the survival of implant biomaterials in vivo, therefore, many investigations focus on
developing appropriate angiogenic scaffolds by implementing angiogenic factors.
One approach is to modify the collagen matrices. Collier et al.  (Collier et al., 2000)
synthesised a biomaterial with polypyrrole-hyaluronic acid, which improves both the
cell compatibility and the vascularisation. Pieper et al. cross-linked
glycosaminoglycans to collagenous materials to preserve porous integrity, promote
angiogenesis and reduce foreign body reaction (FBR) (Pieper et al., 2000b). Another
approach is to deliver growth factors such as FGF, VEGF and ECGF for increasing
angiogenesis, enhancing epithelialization and reducing contraction of wound healing
(Andrade et al., 1987). The third approach is to administrate the various peptides to
the implant biomaterials to study their angiogenic activity in the biomaterials. Both
vasoactive intestinal peptide (VIP) and angiotensin II show angiogenic activity in vivo
and the effect is activated according to the level of their receptors’ level (Hu et al.,
1996). Heparin affinity regulatory peptides were found to have properties that can
stimulate endothelial cell tube formation, migration, and induction of angiogenesis
(Papadimitriou et al., 2000). Substance P, a member of the neurokinin family of
regulatory peptides and acts through cell surface receptors, is able to enhance
angiogenesis through its action on microvascular NK receptors (Walsh et al., 1996).
The last kind of assay is to utilise the ligand of chemokine receptors to bind the
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objective cells to activate its angiogenic effects. The CC chemokine I-309 was found to
bind to endothelial cells, thereby stimulating chemotaxis and invasion of these cells, as
well as enhancing their differentiation into capillary-like structures and inducing
angiogenesis in vivo (Bernardini et al., 2000).
With the change of the structure of the biomaterials, administration of a variety of
growth factors, vasoactive peptides, and certain kind of receptor ligands of the
receptors, angiogenic effects were acquired in the  biomaterials various aspects of
angiogenesis were addressed.  It may be  speculated that by immobilization of
heparin, - several angiogenic growth factors, such as bFGF, VEGF have a high affinity
towards heparin -within the collagen matrices, should be a suitable approach for
developing angiogenic biomaterials for tissue engineering. In addition, heparinized
collagen matrices can enhance their angiogenic effects in vivo and in vitro (van
Wachem et al., 2001; Wissink et al., 2000a). Therefore, investigations focussing on
binding growth factors to heparinized biomaterials could be a way to search for
angiogenic biomaterials. In order to immobilize heparin to collagen matrices, cross-
linking agents have to be added first to activate carboxylic acid of heparin (Hep-
COOH) with highly active N-hydroxysuccinimidyl esters which subsequently react with
NH2-groups of the collagen.
1.3 Cross-linking of collagen matrices
1.3.1 Introduction
Untreated collagen matrices are biodegradable and can be degraded by enzymes
(e.g. collagenase) quickly after implantation. In order to control its degradation rate to
fulfill the various demands needed in tissue engineering, many approaches have been
developed to cross-link collagen matrices. In general, these approaches can be
classified into two kinds of cross-linking methods, namely physical and chemical
method. As to the physical treatment of cross-linking, dehydrothermal treatment (DHT)
and ultraviolet (UV) irradiation were developed to increase the cross-linking rate of
collagen matrices. The primary advantage of such treatments is that they do not
introduce chemicals that cause potential harm. The shortcoming is that the collagen
matrices modified by physical treatment becomes rigid and shrink in form. Chemical
treatment concentrates on creating new additional chemical bonds between the
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collagen molecules by reaction with chemical agents. Most of collagen matrices
modified with chemical cross-linking treatment can maintain much of the original
character of the tissue, such as flexibility and mechanical properties (Khor, 1997).
Among the different cross-linking agents, glutaraldehyde has been investigated
thoroughly. The application of glutaraldehyde leads to high degrees of cross-linking
when compared with other known agents such as formaldehyde, epoxy compounds,
cyanamide and acyl-azides (Jayakrishnan and Jameela, 1996; Olde Damink et al.,
1996). However, cytotoxicity and calcification of glutaraldehyde modified collagen
matrices were observed upon in vivo implantation (van Luyn et al., 1992). Therefore,
researchers embarked on attempts to replace glutaraldehyde as  a cross-linking agent.
Alternatively the water soluble carbodiimide is known to activate the carboxylic acid
groups of collagen, followed by a reaction with an adjacent amino group. The reaction
products of the cross-linking agent may be washed out and will no longer remain
inside the collagen matrices. For these reasons I prefer to apply carbodiimide as the
cross-linking agent in our investigation.
1.3.2 EDC/NHS as a cross-linking agent
The water soluble agent N-(3-Dimethylaminopropyl)-N’-Ethylcarbodiimide (EDC) offers
a method based on the concept of cross-linking  by activation of carboxylic acid groups
to generate cross-links between carboxyl and amine groups, without being
incorporated (Nimni et al., 1987). Addition of the nucleophile N-hydroxysuccini-mide
(NHS) to the EDC solution during cross-linking is based on the suppression of two side
reactions which produce hydrolysis and N-acyl shift (Olde Damink et al., 1996). The
general reaction scheme of EDC cross-linking collagen is as follows (see Figure 2): 1.
activation of the carboxylic acid groups of Asp or Glu residues by EDC to give O-
acylisourea groups. 2. conversion of the O- acylisourea groups into a NHS activated
carboxylic acid group. 3. yielding a so-called zero length cross-link between activated
carboxylic acid groups and amine groups of (hydroxy)lysine (Grabarek and Gergely,
1990). Therefore, EDC/NHS does not remain as part of the cross-link in the matrix
which otherwise can possible release of potential cytotoxic agent, such as
glutaraldehyde (GA). The by-products during cross linking of EDC/NHS (EDC-urea)
are water soluble and can be easily removed by rinsing (Gratzer and Lee, 2001)
(Figure 2).
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After cross-linking with EDC/NHS, collagen matrices in general have a higher
shrinkage temperature as well as an increased resistance towards proteolytic
enzymes as compared to GA. Furthermore, cross-linked collagen shows a lower
tendency to calcify and a better biocompatibility (van Wachem et al., 1994a; van
Wachem et al., 1994b). In addition, it was also shown that this modification promotes
the proliferation of HUVECs in vitro (Wissink et al., 2000c). Finally, EDC/NHS cross-
linked collagen matrices absorb more water than  non-cross-linked matrices, which is
beneficial to cell migration (Park et al., 2002).
Heparin                         EDC
                                                                                                                    NHS
Figure 2    Sequence of reactions in the cross-linking of heparin to collagen
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It was reported that EDC/NHS is stable at pH 7.0, while it is considerably more
reactive at pH 5.0 (Gilles et al., 1990). When used for cross-linking of collagen, it was
observed that the optimal pH of the reaction solution is 5.5 (Olde Damink et al., 1996).
Also heparin has carboxylic groups (Hep-COOH), which enables  EDC/NHS to cross-
link heparin to the amine functions of collagen.
1.4 Immobilization of heparin to collagen matrices
1.4.1 Structure and general functions of heparin
Heparin is a biopolymer belonging to the class of mucopolysaccharides
(glycosaminoglycans, GAGs). It is widely distributed in animal tissues and well known
for its anticoagulant effect. More than 70% of the structure of “conventional” heparin
can be accounted for by repeating disaccharide units consisting of 1.4-linked L-
iduronic acid and D-glucosamine. The iduronic acid residues are O-sulfated at position
2, and glucosamine residues are N-sulfated at position 6, which was unequivocally
confirmed by nuclear magnetic resonance (NMR) spectroscopy (Perlin, 1977). At
physiological pH, the carboxyl and sulfate groups of heparin are ionized. Therefore,
heparin is a strong polyelectrolyte and can easily interact with basic sites of proteins.
Some plasma proteins which normally occur in low concentration were shown to be
retained on heparin affinity columns with high specificity. The well-known time-
honoured antithrombotic effect of heparin may be explained by binding to antithrombin
via a specific high affinity pentasaccharide sequence that is only present in a minor
portion of heparin chains. Binding of the pentasaccharide to antithrombin causes a
conformational change of antithrombin that accelerates by a factor of approximately
one thousand its intensity with thrombin and factor Xa (factor X ) (Hirsh et al., 1998).
Additional to these functions, recently an independent function has been recognized,
which is the involvement of heparin in the regulation of angiogenesis (see Table 1)
(Bombardini and Picano, 1997). Since then, much evidence has been accumulated
pointing to an important role of heparin in the control of angiogenesis.
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Table 1
Classical antithrombotic versus novel angiogenic effects of heparin
Therapeutic Role Antithrombotic (Established) Angiogenic (Hypothetical)
Molecular target Factor Xa, Factor IIa Heparin-binding growth factor
Cellular target None Endothelial and smooth muscle cell
Therapeutic effect Antithrombotic Angiogenic
Molecular cofactor Antihrombin III Adenosine
Timing of effect Minutes to hours Weeks to months
First demonstration 1916 Mclean 1981 Folkman
1.4.2 Immobilization of heparin to collagen matrices by using the
cross-linking agent EDC/NHS
Heparin can be covalently immobilized to collagen matrices by  activating the
carboxylic acid groups by using water-soluble carbodiimide  EDC and NHS. After the
activation of carboxyl groups, heparin immobilizes to collagen matrices by a covalent
linkage between the carboxyl groups of heparin and the free amino groups of collagen
(Nimni, 1983). Since there are many carboxyl groups in heparin, the immobilisation of
heparin on  collagen matrices most likely occurs through a multi-point attachment.
Therefore, after immobilization, heparin will be released upon degradation of the
collagen matrices. It was reported that the optimal reaction buffer for activating the
heparin carboxyl groups is 2-morpholinoethane sulfonic acid (MES), at a pH of 5.6.
The reaction time is found for about 5 to 30 minutes. The longer time will possibly lead
to hydrolysis of EDC/NHS activated carboxyl groups, which results in decreased
amounts of immobilized heparin (Wissink et al., 2001b). After the activation of the
heparin carboxyl groups, collagen biomaterials should be added for immobilizing the
heparin to the collagen. Afterwards, the modified collagen must be extensively washed
with sodium chloride and water to remove the reaction products of EDC/NHS and non
-immobilized heparin (Wissink et al., 2001b).
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Immobilization of heparin in biomaterials has been applied to enhance the
thromboresistance of artificial surface exposed to blood or plasma for many years.
Examples of heparin immobilized biomaterials are artificial vessels, heart valves and
catheters. These devices are not biodegradable in the body (Kang et al., 1996). The
applications of immobilization of heparin to biodegradable biomaterials were most on
drug delivery systems (Ahola et al., 2001; Yang et al., 1999), which can be coated on
vascular prostheses to promote the blood compatibility (Bos et al., 1999a).
Collagen is one of the most widely used biomaterials applied for tissue engineering.
There are a number of investigations focussing on the immobilization of heparin into
collagen matrices, because of the latter being a highly thrombogenic material which
introduces platelet adhesion and aggregation as well as activation of intrinsic blood
coagulation. It was found that immobilization of heparin can reduce platelet adhesion
and aggregation as well as inhibit contact activation (Senatore et al., 1990). Since
endothelial cells perform a key regulatory role in hemostasis, some studies have been
focused on the effects of heparinized materials on endothelial cell proliferation. The
results were not always consistent, some report on an inhibitory effect (Nojiri et al.,
1987) whereas other reports favour the (Bos et al., 1998) proliferative effect on
endothelial cells. The immobilization of heparin into collagen films which were
previously cross-linked lead to a slight inhibition of the endothelial cell proliferation as
compared to collagen matrices which were cross-linked only (Wissink et al., 2001b).
The above observations can be ascribed to the proliferative effects of immobilized
heparin in vitro. It is of interest that when heparinized collagen matrices are applied in
vivo, most reports conclude that they slightly promote vascularization around the
implant sites (van Wachem et al., 2001) and that they improve wound healing (Kratz et
al., 1998)
Recently a number of angiogenic growth factors, such as aFGF, bFGF, VEGF have
been found to have a high affinity towards heparin. Therefore the loading of these
growth factors to heparinized matrices which can protect them against denaturation
and allow for a sustained release in vitro and in vivo, has received much attention (Bos
et al., 1999b; Doi and Matsuda, 1997; van Wachem et al., 2001). Results so far show
that heparinized matrices loaded with bFGF promote the proliferation of endothelial
cells in vitro and increase vascularization in vivo (Wissink et al., 2001b).
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In summary, when heparin is immobilized with biomaterials, it still has the effect of an
anticoagulant (Senatore et al., 1990). Although the results about its proliferative effects
on endothelial cells in vitro are not consistent, it seems that the heparinization may
enhance vascularization in vivo (van Wachem et al., 2001). Further, when loaded with
angiogenic growth factors, results show that this loading promotes angiogenesis
substantially both in vitro and in vivo. Therefore, cross-linking agents such as
EDC/NHS may be applied for covalent binding of heparin into matrices in order to
realize  a sustained release, which is governed by the degradation of such modified
matrices.
1.5 Angiogenic Growth Factors
 1.5.1 Introduction
Growth factors are a family of proteins that act on cells in a hormone-like fashion to
regulate cell activity. They attach to specific cell membrane receptors and direct the
cells intercellular activity. They regulate cell migration, proliferation, matrix synthesis,
and remolding.  Among these  growth factors, there is a family of growth factors which
are angiogenic they enhance  vascularization and angiogenesis  in vitro and in vivo.
Though there are quite some growth factors found to have angiogenic effects, only the
basic Fibroblast Growth Factor (bFGF), the Vascular Endothelial Growth Factor
(VEGF), the Platelet-Derived Growth Factor (PDGF), and the Transforming Growth
Factor ß (TGF-ß) are being investigated intensively.
bFGF belongs to the family of heparin-binding growth factors that has been widely
researched to have the ability of vascular tube formation (Abraham et al., 1986),
enhancing  vascular endothelial cells proliferation in vitro and increasing the number of
blood vessels in vivo (Pieper et al., 2000b). VEGF, a mitogen specific to endothelial
cells in vitro and a potent stimulator of angiogenesis in vivo (Peters et al., 1998), also
has a high affinity towards heparin and will be applied in this study. Therefore I will
introduce its properties in the next paragraph.
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1.5.2 Vascular Endothelial Growth Factor
Vascular endothelial growth factor (VEGF) is a 34- to 42- kD homodimeric glycoprotein
(Senger et al., 1993). It has at least three naturally occurring splice variants: VEGF189,
VEGF165, VEGF121. The three vary in their affinity for heparin, with VEGF121 displaying
a minimal, VEGF165 an intermediate and VEGF189 a strong heparin affinity. Two so-
called tyrosine kinase receptors have shown to function as high affinity receptors for
VEGF, they are the 180 kd fas-like tyrosine kinase (flt-1 or VEGFR-3) and the 200 kd
kinase inset domain-containing receptor (KDR or VEGFR-2). Of the two tyrosine
kinase VEGF receptors, KDR appears to be the major transducer of the VEGF signal
in the endothelial cells (Klagsbrun and D'Amore, 1996; Shen et al., 1998).  Upon
binding to these receptors, VEGF can play a central role in the regulation of
vasculogenesis and angiogenesis.
Studies show that VEGF is a specific mitogen for endothelial cells derived from small
or large vessels (Ferrara and Alitalo, 1999) and is the only growth factor known to act
solely on endothelial cells (Neufeld et al., 1999). VEGF has been shown to be able to
promote the vascular proliferation, migration, and tube formation in vitro and not only
increase the number of blood vessels, but also increase their permeability in vivo
(Clauss et al., 1990).
We speculate that by using VEGF’s high affinity to heparin, it may be possible to bind
the VEGF to heparin immobilised within the collagen matrix.  After physical binding of
VEGF to heparin, VEGF may be protected in a thermo-stable and protease-resistant
form and a sustained release of VEGF could go along with the degradation of the
collagen matrix.  Therefore, the angiogenic potential of modified collagen matrix may
be enhanced by incorporation of VEGF for obtaining a sustained release in vitro and in
vivo.
1.6 Incorporation of VEGF into collagen matrices
1.6.1 Introduction
To overcome the problem of rapid diffusion and clearance from the implant site and
also to increase stability after implantation, VEGF may be bound to collagen matrices
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by means of  several methods. To our knowledge, at least three approaches of
immobilizing VEGF to collagen matrices have been investigated to date. One
approach is to covalently bind VEGF to collagen matrices with a homobifunctional
cross-linking agent e.g. bis-(succinimidylsuccinate)-polyethyleneglycol (SS-PEG-SS).
The method has been applied on binding VEGF to collagen matrices in our laboratory
before and it can successfully covalently bind VEGF to collagen with sustained release
in vitro (Chen, 2001; Chen et al., 2002).  A second approach is to incorporate VEGF
into biodegradable microspheres obtained with the emulsion/solvent extraction
technique, subsequently these spheres are homogeneously  mixed in the collagen
suspension and lyophilized (Peters et al., 1998). These two approaches for
incorporation of VEGF  could be defined as chemical method because of the cross-
linking and the encapsulate agents are inside the matrices which may have some
influence after implantation. A third approach is to incorporate VEGF into collagen
matrices by physical binding to heparin which was immobilized inside before. In this
approach the growth factors will not be immobilized covalently.  I will apply this
approach in our study.
1.6.2 Physical binding of VEGF to heparinized collagen matrices
As mentioned before, VEGF is a angiogenic growth factor with a high affinity towards
heparins (Shing et al., 1984). Therefore, it might be possible to preserve VEGF inside
collagen matrices as a reservoir immobilized to heparin covalently linked to the
collagen. Another advantage of this approach is that after binding to heparin, the
binding of VEGF to receptors on vascular endothelial cells may be potentiated by
prevention of the inactivation of VEGF by α-2 macroglobin (Soker et al., 1993).
There are reports demonstrating that bFGF binds to heparinized collagen films
(Wissink et al., 2001b; Wissink et al., 2000a). In this study the collagen film was first
cross-linked with EDC/NHS. The heparin was subsequently immobilised in the cross-
linked collagen films. Thereafter, the heparinized collagen films were immersed in
different concentrations of bFGF solutions and incubated for 90 min at room
temperature.  The results show that as compared with non-heparinized cross-linked
collagen films, the amount of bFGF binding in heparinized collagen film is much higher
and the release is sustained at a relative low rate. In addition,  the bioacitivity of bFGF
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in the heparinized collagen film was - as evaluated by the vascular endothelial cell
proliferation assay - better than that of bFGF simply admixed to non-heparinized
collagen.  Their experiment results encouraged us that it may be possible to another
growth factor with a high affinity towards heparin i.e. VEGF, the action of which is
restricted to vascular endothelial cells (Ferrara et al., 1992).  To our knowledge,  no
such investigations have been reported to date.
1.7 Methods to evaluate the characteristics of modified
collagen matrices
1.7.1 Quantification of immobilized heparin
For the determination of the amounts of immobilized heparin I  made use of the
procedures as published in 1996 (Walsh et al., 1996). The assay is based on the
capacity of heparin to complex with toluidine blue and can be solubilized in a mixture
solution of NaOH and ethanol. By measurement of the absorbance of the solution at
530 nm using a spectrophotometer, the amount of immobilized heparin can be
calculated from a calibration curve obtained with the toluidine blue solution assay (van
Wachem et al., 2001). Indeed, an alternative method to evaluate the amount of
immobilized radio active labeled heparin (³H-Heparin) has been applied (Walsh et al.,
1996). This method can determine very low amounts of heparin in solution and is,
however, usually applied for the determination of heparin release from heparinized
biomaterials.
1.7.2 Moisture uptake
Collagen molecules are known to bind a large amount of water. Cell adhesion and
blood coagulation are two fundamental events that can occur on the surface of implant
materials (Jansen et al., 1989). Cell adhesion is required for incorporation of implants
into tissues, while thrombogenicity is less desirable. Unfortunately, collagen is a
thrombogenic substrate (Silverstein and Chvapil, 1981). The adhesion of anchorage-
dependent cells and the induction of a thrombosis depend on numerous factors,
among which, the equilibrium aqueous content seems to be the most important (Lydon
et al., 1985). Different cross-linking treatments can modify the surface of collagenous
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materials and thus change their thrombogenicity (Cote and Doillon, 1992). It has been
reported that heparinization and cross-linking of collagenous materials  promote the
moisture uptake, reduce the adhesion of platelets and increase albumin absorbance
(Chuang et al., 2001).
There are two methods to test the moisture uptake of modified materials. One is
aqueous contact which was measured by using a goniometer and surface tension
which was developed by Kaelble and Moacanin (Yang et al., 1997). The other is by
measurement of the different weights before and after the materials being immersed
into an aqueous phase and after having reached equilibrium (Gao et al., 2002).
Generally, the results are in agreement with each other.
1.7.3 Determination of the in vitro degradation
Collagen based materials is biodegradable into body because of varies enzymes will
cleave the peptide bond within the triple helical of collagen. The stability of collagen
materials towards enzymatic degradation can be improved by cross-linking (Lee et al.,
1996). Through evaluation of their degradation degree by enzymes, the cross-linking
degree of collagen materials can be detected. Several enzymes may be used for
evaluating the degradation behaviour of modified collagen matrices. They are the
bacterial collagenase, cathopsin and trypsin (Zeeman, 1998b).
The bacterial collagenase isolated from Clostridium histolyticum is capable of cleaving
peptide bonds within the triple helical structure of collagen and has a specificity for
Pro-X-Gly-Y sequences, cleaving between X and Gly. X and Y are predominantly
apolar amino acid residues (Harper et al., 1972). The molecular weight of collagenase
is between 68 and 125KD. In a first approximation of a spherical shape, the radius of
gyration will be between 2.8 and 3.9 nm, which implies that collagenase probably will
start at surface of fibrils (Olde Damink et al., 1996). Investigations so far have shown
that collagenase initially absorbs onto fibers of collagen and during degradation,
collagenase can penetrate into the fiber. After being treated by EDC/NHS, cross-links
are formed among polypeptide chains of the collagen. They hinder penetration of
collagenase into fiber, which results in decreasing the degradation by collagenase.
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From the above, it may be concluded that the evaluation of the degradation behaviour
of modified collagen matrices by collagenase will allow for a prognosis for the
resistance against the enzyme attack after implantation in vivo. This prognosis may be
meaningful for controlling the degree of biodegradation of engineered tissues.
1.7.4 Determination of free amino groups
Collagenous materials are proteinaceous materials whose lysine is one of the
essential amino acids. Several chemical cross-linking agents, such as GA, EDC/NHS ,
modify the structure of collagen by the reaction between  carboxylic acid groups and ε-
amino groups. Heparin immobilized in the collagenous materials by EDC/NHS is
through activation of carboxylic acid groups of heparin and then react with ε-amino
groups  of collagen. Therefore, by determination of the number of ε-amino groups in
the modified collagenous materials, the cross-linking degree can be evaluated.
A method which is often applied is the quantification of the  ε-amino groups in the
collagenous materials is by using trinitrobenzenesulfonic acid (TNBS) (Cayot and
Tainturier, 1997). TNBS, as a UV-chromophore, reacts with primary amino groups of
proteins at an alkaline pH to form a trinitrophenyl derivative and a sulfate ion. By
measurement of the yellow absorbance of the trinitrophenyl derivation, the number of
ε-amino groups in protein can be calculated. It needs to be pointed out that an
extraction step should be introduced to remove both the excess unreacted TNBS and
TNP-α-amino derivatives (Kakade and Liener, 1969).
1.8 Evaluation of the angiogenic potential of modified matrices
1.8.1 Chorioallantoic Membrane (CAM)  Assay
The chorioallantoic membrane (CAM) of the chicken embryo, which serves as the
embryonic respiratory organ (Billett et al., 1965), is a highly vascularized membrane
which lines inside the surface of egg shell and is relatively thin and transparent. Its
two dimensional vascular structure can be seen entirely with minimal preparation. This
is one of the major reasons it has become a popular assay tissue for putative
angiogenic and antiangiogenic substances (Weis et al., 1991). In addition, the CAM
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assay is relatively cheap, easy to operate and has less ethical concerns as compared
to other in vivo angiogenesis assays .
However, the methods to quantify the extent of the angiogenesis or vascularization in
the chorioallantoic membrane are somewhat troublesome. They have been many
efforts developed at quantifying the number.  For example, one method is to estimate
the DNA and protein synthesis in the chorioallantoic membrane for the reason of the
more neovascularization, the more DNA and protein synthesis in the chorioallantoic
membrane (Thompson et al., 1985). The other method is morphometric measurement
of microvessels of the chorioallantoic membrane by counting the number of “vessel
endpoints “ with or without the assistance of a computerized image analysis system
(Neufeld et al., 1999). Later, a fractal analysis was applied on the method of
morphometric measurement which was reported to be more accurate, reproducible
and objective since the morphometric form of the vessels in the chorioallantoic
membrane poses hierarchical branching patterns (Kirchner et al., 1996).
Many angiogenic factors have been investigated by using the CAM assay, they include
bFGF and VEGF. The results show that bFGF stimulates angiogenesis associated
with hyperplasia of chorion and fibroblast cell proliferation and its antibodies inhibit
such effects (Ribatti et al., 1997). In general, VEGF has the same effects as that of
bFGF. In addition, VEGF transfectants were found to be able to induce neovasculature
with open junctions and a fenestrated endothelium (Ribatti et al., 2001).  This means
that VEGF may have a strong angiogenic potential in vivo in this model.
However, to my knowledge, up to date, there is no report investigating the angiogenic
potential of modified collagen matrices with a sustained release of VEGF by applying
the CAM assay. I think it should be of prime interest to evaluate the  angiogenic
potential by this method.
1.8.2 Animal experiments
Although the CAM assay has some advantages in the evaluation of the angiogenic
potential of biomaterials in vivo,  there are still several limitations by using the assay.
For example, the time of this assay is limited to 21 days because of the development
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of the embryo. The total volume of blood inside the chorioallantoic membrane of
embryonated eggs is relatively small  as compared to that of  animals  because of the
limited weight of the embryos. Moreover it is rather difficult to quantify the hemoglobin
content and blood flow inside implants. Therefore, the CAM assay cannot completely
replace the animal experiments to date.
Several animal model experiments have been developed to evaluate the angiogenic
potential of biomaterials in vivo. They include the rabbit corneal model (Gimbrone et
al., 1974), the hamster cheek pouch model and the rodent subcutaneous model
(Andrade et al., 1987). Among them, the rodent subcutaneous model is the most
widely applied. With the help of recent subcutaneous model experiments, the
morphometric neovasculature analysis (Mayhew and Sharma, 1984), the quantification
of hemoglobin content of angiogenesis (Teixeira and Andrade, 1999) and the
measurements of the pharmacological reactivity of the neovasculature in the
vascularized implants (Andrade et al., 1997) have been successfully applied. Among
these, I think that the hemoglobin content inside implants may represent the amount of
blood flow inside such implants to supply the nutrients for cell survival.  Therefore, the
hemoglobin content of the explants may be an important parameter for evaluating  the
angiogenic potential of implants in vivo.
1.9 Aim of the thesis
In the present thesis, I embark on taking collagen as the starting material for
developing a tissue substitute. The biodegradable collagen matrix, which is
characterised by a porous and fibrillar structure, is - since its  properties meet many of
the required criteria - one of the most widely used materials for tissue engineering
(Boyce et al., 1988; Doillon et al., 1994a).
However, as mentioned before, one of the primary factors that challenge the prospects
of tissue engineering is the insufficient supply of blood and nutrients in the engineered
tissue after implantation into the body. This supply is necessary for the living cells to
grow and survive. A variety of angiogenic growth factors have been discovered
recently,  which induce vascular endothelial cell proliferation and migration, as well as
vascularization. Among them, vascular endothelial growth factor (VEGF) is specific for
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endothelial cells and a potent stimulator of angiogenesis in vivo (Peters et al., 1998;
Plate and Warnke, 1997). Therefore, the incorporation of angiogenic growth of VEGF
represents a promising approach to enhance the angiogenic potential of engineered
tissue substitutes. Thus, VEGF may stimulate endogenous vascular endothelial cells
to proliferate and migrate into the tissue substitute, and finally form blood vessels.
It is known that the in vivo half life of VEGF is very short (Veikkola et al., 2001) since it
can be denatured easily.  Therefore, the realization of collagen matrices which bind,
protect and release angiogenic growth factors, such as VEGF, in a therapeutic manner
should be one of the major goals on our way to develop a tissue substitute with
enhanced angiogenic capabilities.
It has been reported, that the angiogenic growth factors bFGF and VEGF have  high
affinities for heparin and that they become more stable and more active after binding
to the heparin (Gospodarowicz and Cheng, 1986; Sommer and Rifkin, 1989).
It seemed therefore desirable to develop collagen matrices with different amounts of
immobilised heparin using the cross-linking agent EDC/NHS. By applying different
EDC/NHS to heparin ratios one expects to obtain collagen matrices with different
amounts of immobilized heparin and different resistances towards degradation. I
speculated that the release of VEGF from these differently modified collagen matrices
depends on their amounts of immobilized heparin and their degradation behavior.
Thus, the aim of the presented work was to develop collagen matrices which differ in
the amounts of immobilized heparin and in the in vitro degradation behaviors. In order
to evaluate the biochemical properties, the number of primary free amino groups and
the moisture uptake was investigated.  Finally, the angiogenic potential of these
modified matrices was investigated by exposure to the chorioallantoic membrane of
the chicken embryo (CAM assay) and to subcutaneous tissue in animal model
experiments.
In overview,  the main objectives of this study are:
1 Modification of collagen matrices by cross-linking with appropiate cross-
linking agents.
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2 Incorporation of heparin into collagen matrices for providing binding sites
for immobilizing the angiogenic factor VEGF.
3 Chemical and physical characterization of the modified collagen matrices.
4 Evaluation of the angiogenic potential of the modified collagen matrices
with the chorioallantoic membrane of the chicken embryo.
5 Evaluation of the angiogenic potential of the modified collagen matrices by
subcutaneous implantation in rats.
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2 Materials and Methods
2.1 Collagen Matrices
Collagen matrices were prepared according to a freeze-drying procedure to achieve
matrices with a non-directed porous microstructure. The basic material is a collagen
suspension containing 1.8 wt.-% of type 1 collagen isolated from bovine skin (Dr.
Suwelack Skin & Health Care AG, Billerbeck, Germany) in acetic acid (pH 2,8)
(Matristypt: Kollagen-Matrix, Ch: 226911). For the cell culture, CAM assay and animal
model experiments, the matrices were sterilized with 70% ethanol. Briefly, the (non-)
modified matrices were immersed into 70% ethanol for 24 h. Then under sterilized
condition, the samples were transferred into 0.9% NaCl (24 h) and cell culture medium
(24 h).
2.2 Modification Procedures
The collagen matrices were cut into cubes of either 5*5*5 mm (3.8–4.2 mg)  for
determination of the modification parameters, or into dics of 10 mm of diameter, 2 mm
and 5 mm thick (3.8– 4.2 mg and 11.5-12.5 mg rep.) for determination of their
angiogenic potential with CAM-assays  and animal model experiments respectively.
The modification procedure was in principle performed as described by Wissink et al
(Wissink et al., 2001b). The main difference is that the procedure of Wissink et al. is
described for collagen films and that in their procedure the collagen matrices were in
all cases cross-linked with EDC/NHS prior to the cross-linking of the heparin.
Then carboxylic acid groups of heparin (Hep-COOH) were activated with EDC/NHS,
whose weight ratio was fixed at 1 : 0.6. Defined amounts of EDC/NHS were added to a
solution of heparin at various weight ratios. The EDC to heparin ratio was varied form
0.2 to 4.
The modification parameter H1E1 refers to 1 mg heparin and 1 mg EDC/0.6 mg NHS
per 500 µl reaction mixture, H4E3 refers to 4 mg heparin and 3 mg EDC/1.8 mg NHS
29
and H0E0 refers to non-modified collagen. Heparin (sodium salt, 170 USP units/mg),
EDC and NHS were purchased from Sigma-Aldrich.
Heparin is activated with EDC/NHS for 10 minutes at 37°C in 0,05 M buffer of 2 –
morpholinoethane sulfonic acid (MES buffer, pH 5.6) (K 28866628 131, Merck KgaA,
64271 Germany). After activation, collagen matrices are - under gentle shaking -
immersed into the reaction mixture and incubated for 4 h at 37°C. After this reaction,
collagen matrices are intensively washed with 0.1 M Na2H2 PO4 (2 h), 4 M NaCl (4
times in 24 h) and distilled water (5 times in 24 h). Thereafter, the modified collagen
matrices are frozen at –80°C overnight and then lyophilized. After lyophilization, the
collagen matrices are stored at room temperature until use.
2.3        Determination of immobilized heparin in collagen
matrices
The amount the heparin immobilised in the modified collagen matrices is determined
by using the toluidine blue assay (Hinrichs et al., 1997). Cubic collagen matrices are
incubated with 5 ml aqueous solution of toluidine blue (0.1 M HCl, 2 mg/ml NaCl, 0.4
mg/ml toluidine blue zinc chloride double salt (Sigma)) for 4 h at room temperature,
resulting in complexation of toluidine blue with heparin. Afterwards, the collagen
matrices are washed with distilled water (10 ml per sample) 5 times overnight.
Subsequently, toluidine blue complexed to heparin of one sample is solubilized  with 5
ml of a 1:4  (v/v) mixture of 0.1 M NaOH and ethanol. The absorbance of the resulting
solution is determined at 530 nm after 1:5 dilution with the sodiumhydroxide/ethanol
solution. Standard curves were obtained with the heparin solution assay (Hinrichs et
al., 1997) which is described briefly as follows.
0, 0.1, 0.2, 0.4, 0.8, 1.0, 1.2 mg of heparin are dissolved in 2 ml aqueous of 0.1N
HCl/0.2% NaCl respectively. Then add 2 ml of 0,04 wt% toluidine blue to each of the
samples and allow to react for 4h at room temperature under gentle shaking, this
reaction results in complexation of toluidine blue with heparin leading to a precipitating,
non-soluble complex. Afterwards,  the samples are centrifuged at 3000 g for 10
minutes and then  the supernatant is decanted. The precipitate is rinsed with aqueous
0.1N HCl/0.2% NaCl for three times and centrifuged after each time of rinse.
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Thereafter, the precipitate is dissolved with 5 ml of 4:1 (v/v) solution of ethanol to 0.1M
NaOH. The absorbance of the resulting solution is read at 530 nm after 1:10 dilution
with the sodiumhyroxide/ethanol solution.
2.4 In vitro Degradation
The degradation of collagen matrices is evaluated through the difference of their
weights before and after the in vitro degradation by the bacterial collagenase
(Clostridium histolyticum type 1, 232 u/mg, CLS 1, Worthington Biochemical
Corporation) at different concentrations for a defined period of time. First, the  weight
of the modified collagen matrices (size: 5*5*5 mm ) are determined immediately after
lyophilization. Then  each of such samples are immersed into 500 µl of the
concentrations of either 40 units or 200 units collagenase /ml and incubated at 37°C
under gentle shaking for variable periods of time. The degradation is terminated by
adding 20 µl of  0.25 M ethylenediamine-tetraacetate (EDTA) (pH 6.7) (Sigma) and
cooling on ice.  After 10 minutes, the solution of EDTA is decanted and washed with
10 ml of phosphate buffer solution (PBS) (pH  7.2) per sample 3 times for 30 minutes,
followed with 10 ml of distilled water 3 times for 30 minutes. After the washing
procedure, the samples are frozen and lyophilized again. After lyophilization, the
remaining weight of each sample is determined by the same electronic balance. The
weight loss of collagen matrices, expressed as the  percentage of initial weight
remaining which represent the degradation percentage,  calculated as the formula as
below:
Degradation (%) = ( Wi – Wd ) / Wi ∗ 100
Wi represents the original weight of each sample, Wd represents the weight of the
corresponding sample after the degradation in the presence of collagenase.
2.5 Determination of free amino groups
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The primary amino group content (lysine and hydroxylysine residues) of  modified
collagen matrices is determined using 2,4,6–trinitrobenzenesulfonic acid  (TNBS).  To
a modified collagen sample, 1.0 ml of 4 wt% NaHCO3 solution (pH 9.0) and 1.0 ml of a
freshly prepared 0.5 wt% TNBS (P-2297, Sigma-Aldrich) solution in distilled water is
added. After reaction overnight at 40°C, 3.0 ml of 6 M HCl is added and the
temperature is raised to 60°C for 90 minutes to solubilize the collagen matrices. The
blank is prepared by the procedure except for the HCl which is added before the
addition of TNBS to prohibit any reaction of TNBS with the protein. The resulting
solution is extracted with  20 ml portions of diethylether (Merck Schuchardt, 85662
Hohenbrunn, Germany) for five times to remove excess untreated TNBS and TNP-α-
amino groups, followed by evaporating  the residual ether in a hot water bath for 15
minutes. Thereafter, the 1 ml of the aliquots is diluted with 9 ml of distilled water and
the absorbance is measured at 345 nm with a spectrophotometer. The number of free
amino groups per 1000 amino acids in collagen matrices is calculated by the formula
below:
Free amino groups = (Absorbance at 345 nm) ∗(0.05 liters ) (MW) / (1.46∗10000 liters/
mole .cm)∗ (b) ∗ (x)
Where MW is the molecular mass of the collagen in g/mol, 1.46 ∗ 10000 liter/mol.cm is
the molar absorptivity of TNP-lysine, b is the cell path length in cm, and x is the
sample weight in gram.
2.6 Determination of the moisture uptake
The moisture uptake of the modified collagen matrices are determined by the
measurement of their ability to keep the amount of liquid. First,  the initial weight each
sample using for moisture determination is determined with a electronic balance
immediately after lyophilization, followed by  immersion  in 1 ml of PBS buffer (pH 7.2)
at 37°C and incubation for 2 h. Subsequently the samples are taken out  and exposed
to a piece of filter paper until no water was soaked out of the matrix any more. Then
the weight of each sample is determined. The moisture uptake of each sample is
calculated with the formula:
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Moisture uptake = ( Wwet – Wdry ) / Wdry
Wwet represents the sample weight after moisture uptake and exposure to the tissue
paper. Wdry denotes the weight of the lyophilized specimen before uptake of the
moisture.
2.7 Evaluation of the angiogenic potential of the modified
collagen matrices with  the chorioallantoic membrane
assay (CAM)
The angiogenic potential of the modified collagen matrices is determined with
chorioallantoic membrane assay (CAM). The  eggs for the experiment are cleaned and
disinfected with 70% ethanol, followed by incubation at 37°C for 7 days. Afterwards,
the fertilized eggs are selected for further experiments. First, one hole is drilled on the
larger end of egg with the membrane beneath shell  being thrusted broken, followed by
drilling another hole on top of horizontally placed egg in opposite to the embryo with
the membrane intact. Subsequently, a small amount of ice is put on the top hole for 5
min, followed by ethanol disinfecting and thrusting the membrane beneath the top
hole. Thereafter, a triangular window is opened by using an electronic drill knife
without damaging the chorioallantoic membrane.  The window should be immediately
covered with a piece of parafilm to prevent dehydration and contamination. Next, the
sterilized modified collagen matrices were placed on the CAM in laminar flow.
Aqueous (100 µl) solutions containing 30 ng or 100 ng of rhVEGF is pipetted inside the
sample if necessary, followed by covering the window and taking the eggs out of the
laminar flow. Thereafter, sealing tape and another hole of the shell on the larger end of
the egg are sealed by using liquid wax. At last, all the eggs are put into an incubation
container for another 7 days at 37°C for the angiogenic potential evaluator. Below is
the scheme of the CAM experiment:
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                                                                                                                Parafilm
                                                                                                                Sample
 Hole
 Window
Figure 3 Scheme of the CAM experiment before incubation
After incubation for 7 days, the following steps ensued :
1. The parafilm was remove from the window of  each egg and the window was
enlarged up to the border of chorioallantoic membrane without damaging the
membrane.  Below is the scheme of this step:
                                                                                                       Enlarged window
Figure 4  Situation of the chorioallantoic membrane experiment with enlarged
window after the incubation period
2. Photos were taken of on each enlarged window. The macroscopic changes of
each sample in the CAM were recorded, including the death rate of eggs, area
reduction of the (non-) modified samples, vessels form beside the samples, the
overgrowth granumatous tissue engulfed by the CAM.
3. 3.5% formaldehyde was dropped on the top of CAM under the window for fixing
of CAM in situ. After 3 minutes, 3.5% formaldehyde was sucked with a paper
and the CAM was dissected near the implant  (collagen matrices). The area is
about 1.5 cm * 1.5 cm.  Then the implant was excised carefully and put into a
tube with 3 ml of 3.5% formaldehyde for histological examination.
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4. The excised CAM was immersed into water in order to obtain a flat excision,
then the excised membrane was mounted on a microscope glass slide and
fixed with a fixative solution (Hydromount).
5. The number of capillaries was counted with a light microscope equipped with a
121 points grids under 50 times magnification.
2.8 Evaluation of the angiogenic potential by determination of
the hemoglobin content of explanted matrices after
implantation into rats for 15 days
The collagen matrices of 10 mm in diameter, 5 mm in thickness was made for animal
experiments. The samples were first modified with heparin immobilisation, EDC/NHS
cross-linking, whose procedure was the same as that of H1E1 and H0E1. Afterwards,
the weight of each sample was evaluated immediately after lyophilization. Thereafter,
the samples were sterilized with 70% of ethanol (see the procedure of sterilization)
before implantation in the Lewis rats. Rats of approximately 300 mg weight were ether
anaesthetized. Then the rat’s back was shaven and disinfected, four beside midline
incisions of 1 cm were created. A total of four pockets were created laterally to the
incisions. One sample was placed in each pocket, care was taken to implant the
materials completely flat. Before explantation, rats were ether anaesthetized to be
sacrificed. Implants were taken out after 15 days implantation. For the determination of
hemoglobin, the  fibrotic capsules adhering to the samples were excised carefully.
Figure 5 shows a schematic representation of the animal experiment.
Hemoglobin determinations were done by spectrophotometer.  First the standard
curve was made by correlation of different amounts of standard myoglobin (29895,
SERVA; Feinbiochemica, Heideberg) which replaces standard myoglobin in our
experiment and their maximal OD at around 410 nm. Then the implants were taken
out, they were first immersed into 1 ml of distilled water for 5 minutes to wash out the
hemoglobin attached  to the surface, then the samples were
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      H0E0                               H0E0+VEGF§        H1E1                           H1E1+VEGF§
       H0E0                              H0E0+VEGF§       H1E1                          H1E1+VEGF§
              H0E1                           H0E1+ VEGF§
               H0E1                           H0E1+VEGF§
§: each of modified collagen matrices were loaded with 300 ng of rr-VEGF165
Figure 5    Schematic representation of the animal experiments. Implantation site on
dorsum of rat.
put into another 1 ml of distilled water for 24 h under gentle shaking to wash out the
hemoglobin contained in the samples. Afterwards, these samples were digested
completely with 1 ml of 1000 units of collagenase. The absorbances of water and
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collagenase solutions of the hemoglobin were determined at 410 nm (Soret band). The
absorbances were used for calculation of the hemoglobin contents in microgram per
ml with the help of a standard curve obtained with sperm whale myoglobin
(29895,SERVA, Feinbiochemica, Heidelberg, Deutschland). For this purpose 1 mg
sperm whale myoglobin was dissolved in  1 ml of water, aliquots with 0.05 – 0.3 mg
myoglobin per ml were used for obtaining the standard curve.
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3 Results
3.1 Immobilisation of heparin
3.1.1 Search for optimal immobilization conditions
The main aim of this thesis was to develop a collagen matrix with enhanced
angiogenic capabilities. This goal may be achieved by incorporating angiogenic factors
into these matrices. Since the most potent angiogenic growth factor VEGF165 disposes
of a domain which binds with high affinity to heparin (Tessler et al., 1994), Idecided to
covalently link heparin to collagen by means of the cross-linking agent EDC/NHS. For
this purpose Iadopted the procedure of Wissink et al. (Wissink et al., 2001b). In
contrast to their procedure I performed the modification in one single step.
In order to be able to evaluate and determine the extent of incorporated heparin
Idetermined a calibration curve (Figure 6) by means of the method of Hinrichs et al.
(Hinrichs et al., 1997)
Figure 6  Calibration curve used for the determination of immobilized heparin.
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My primary goal was to look after optimal reaction conditions. Optimized reaction
conditions should lead to maximal heparin immobilisation in combination with an
optimized degradation behaviour. Initially, 4 different reaction procedures were
investigated for evaluation of their heparin immobilisation and their resistance versus
degradation. These procedures are 1. (H+E)+C: 1 mg heparin/500 µl were allowed to
react for 10 min with 1 mg EDC/NHS /500 µl , the collagen specimens wereimmersed
into this solution and incubated for 4 h at 37°C under gentle shaking, 2. (H+E+C):
specimen were immersed into the solution of 1mg heparin/500 µl  and 1 mg
EDC/NHS/500 µl and incubated for 4h and 10 minutes. 3. (H+C)+E:  specimens were
immersed into mg heparin/500 µl for 10 minutes, subsequently 1 mg EDC/NHS/500 µl
was added and incubated for 4 h. 4. (H+C+L)+E: collagen specimen were immersed
into a solution of 1 mg heparin/500 µl and lyophilized,
Figure 7 Heparin immobilisation and in vitro degradation obtained with the different
reaction procedures. Reaction procedures were performed as described in Materials
and Methods and explained in the text. Degradation was carried out with 40 units
collagenase in 1 ml of  PBS buffer for 2 h at 37°C. Columns show mean values, error
bars represent the corresponding standard deviations (n = 5).
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After lyophilization the dry specimens were allowed to react in a solution of 1 mg
EDC/0,6 mg NHS per 500 µl. The results of Figure 7 show that the amount of heparin
immobilisation is maximal with procedure 1. The different procedures do not lead to
large differences in the in vitro degradation behaviour among the procedure 2, 3, 4, I
therefore selectedprocedure 1 (H+E)+C for further experiments. I then optimized the
reaction time, the results of Figure 8 demonstrate that an incubation time of 4 h led to
maximal heparin immobilisation. Based on these results, I selected the procedure
(H+E)+C and reaction time for 4 h as the optimized reaction condition for further
experiments.
Figure 8   Heparin immobilisation in collagen matrices H1E2 and H1E4  as a function
of reaction times varying from of 0.5 to 4 h (n=1).
3.1.2 Heparin immobilisation as a function of varying EDC/NHS
to heparin ratios.
As shown in Figure 9, heparin immobilisation increases with increasing weight ratios of
EDC/NHS to heparin, it reaches a plateau at a ratio of 2:1. Further increase of the ratio
to 4:1, does not lead to higher immobilisation. Maximal heparin immobilisation
amounts to 40 µg heparin immobilised per 1 mg collagen.  Figure 10 furthermore
shows that virtually no heparin was bound in the absence of the cross-linking agent
(H1E0). This demonstrates that virtually no heparin is adsorptively bound and the
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extensive washing procedure has apparently removed all non-covalently bound
heparin.
Figure 9   Heparin immobilisation assay as function of increasing weight ratio of
EDC/NHS to heparin. The columns show the mean values, the error bars represent
the corresponding standard deviations  (n=5).
Figure 10    Heparin immobilisation as a function of increasing weight ratios of heparin
to EDC/NHS. The columns show the mean values, the error bars represent the
corresponding standard deviations (n=5).
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3.1.3 Heparin immobilisation as a function of different ratios of
heparin to EDC/NHS
What Figure 10 shows are in contrast with our expectations. By increasing the ratio of
heparin to EDC/NHS, no additional heparin immobilisation was achieved. The higher
ratios (w/w) of heparin to EDC/NHS led to lower extents of heparin immobilisation. The
trend of this reduction slowed down with increasing amount of EDC/NHS involved in
reaction. From H1E0.2 to H4E0.2, the amount of immobilized heparin was reduced by
50 %, from H1E0.5 to H4E0.5, the heparin immobilisation was reduced by about 30 %.
This trend became less prominent by comparing the heparin immobilisation of H1E1
and H4E1, as well as H1E2 and H4E2.
3.2 In vitro degradation of modified collagen matrices
Figure 11 shows the results of a series of in vitro degradation experiments. Modified
collagen matrices  were immersed into a solution of 40 units collagenase/1ml and
incubated at 37°C for 2 h and the weights before and after the degradation were
determined. From these weights, the degradation percentages were calculated as
described in Materials & Methods. The results show that with increasing EDC/NHS to
heparin ratios, the degradation percentages decrease gradually. Whereas the matrices
H0E0 and H1E0.2 were almost 70 % degraded, the matrices H1E0.75 to H1E4 were
degraded to percentages < 10 . The relatively sharp dro between H1E0.2 and
H1E0.75 will be discussed in chapter 5.
Under the conditions used, only small differences in degradation behaviour were
observed for the modification parameters H1E1, H1E2, H1E3, H1E4 (all less than 10%
degraded). In the next set of experiments, I changed the collagenase concentration to
200 units/ml and the incubation times to 2, 6, 24 and 48 h. The results are shown in
Figure 12. Collagen matrices H1E1 are under these conditions degraded to
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Figure 11   In vitro degradation of collagen matrices modified according to parameters
specified in Materials & Methods. Degradation was carried out with 40 units
collagenase in 1 ml of  PBS buffer for 2 h at 37°C.
substantially larger extents: after 24 h these matrices were almost completely
degraded. H1E2 matrices were degraded to about 54.5% ± SD 4.3 %  after 48 h. The
matrices H1E3 and H1E4 were very resistant to the action of collagenase, even after
48 h the matrices H1E4 were only degraded to about 16.5% ± SD 2.4 % .
Figure 12  In vitro degradation of heparinized and cross-linked collagen matrices as a
function of time. Degradation was carried out with 200 units collagenase per 1 ml of
PBS buffer for different periods of time at 37°C. Columns show mean values, error
bars represent the corresponding standard deviations (n=5).
In order to detect if there is any influence of the heparin immobilisation on the cross-
linking  of the collagen matrices, I further evaluated the degradation of collagen
matrices which were modified by EDC/NHS cross-linking only. Primarily, I determined
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the degradation of H0E0, H0E0.2, H0E0.5, H0E1 with 40 units collagenase/ml and an
incubation period of 2 h at 37°C.  The results are shown in Figure 13. The degradation
of H0E0.2 dramatically decreased as compared to H0E0. When, however, the cross-
linking was performed in the presence of heparin the degradation percentage of
H1E0.2 did not not differ very much from H0E0 (see Figure 12). This observation will
be dealt with in the Discussion (chapter 4).
Figure 13  In vitro degradation of non-heparinized, cross-linked collagen matrices.
Degradation was carried out with  40 units collagenase in 1 ml of  PBS buffer for 2 h at
37°C. Columns show mean values, error bars represent the corresponding standard
deviations (n=5).
For the same reason as discussed earlier, I applied higher collagenase concentrations
(200 units/1 ml) and longer periods of incubation (24 h) for better discrimination
between the various degradation behaviours. Figure 15 demonstrates that the
resistance versus degradation increases with increasing EDC/NHS to heparin ratios
(w/w).
Based on the results of Figure 14, I may conclude that the presence of heparin in the
reaction solution has important consequences for the cross-linking by EDC/NHS.
Therefore, I thought that it was of interest to investigate the influence of different
heparin to EDC/NHS ratios (w/w) on the cross-linking of modified collagen matrices.
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Figure 14   In vitro degradation of collagen matrices which were cross-linked only.
Degradation was carried out with  200 units collagenase in 1 ml of  PBS buffer for 24 h
at 37°C (n=5)
I selected the following modification parameters: H1E0.2 H1E0.5, H1E1, H1E2  to
H4E0.2 H4E0.5, H4E1, H4E2. Within the series H1E0.5 to H4E0.5, the degradation
increased from about 60 % to 75 %, within the series H1E2 to H4E2, the degradation
increased from about 10 % to 65 % (see Figure 15). Here again, the heparin to
EDC/NHS ratios (w/w) during the activation played a major role in the degree of cross-
linking.
Figure 15   In vitro degradation of collagen matrices modified according to parameters
specified in Materials & Methods. Degradation was carried out with  40 units
collagenase per ml PBS buffer for 2 h at 37°C. Columns show the mean values, error
bars represent the corresponding standard deviations (n=5)
The next two figures inform about the comparison of the cross-linking effect of
EDC/NHS in the presence and absence of heparin in the reaction solution. Figure 16
shows the degradation under the following conditions: 40 units collagenase/ml and
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Figure 16  Comparison of the in vitro degradation of matrices, which were both heparinized
and cross-linked and matrices, which were cross-linked only. Degradation was carried out with
40 units collagenase per ml PBS for 2 h at 37°C. Columns show the mean values, error bars
represent the corresponding standard deviations (n=5).
incubation at 37°C for 2 h. The presence of heparin in the reaction solution appears to
have is a dramatic effect on the degradation behaviour of the modified matrices
H1E0.2 and H0E0.2 as well as H1E0.5 and H0E0.5. Figure 17 shows the degradation
under the condition of 200 units collagenase/ml and incubation at 37°C for 24 h. More
pronounced differences of the degradation are observed between H0E1 and H1E1 as
well as between H0E2 and  H1E2. The degradation percentages range from 10 to 95
and 15 to 35, respectively
Figure 17  Comparison of in vitro degradation  of  heparinized and cross-linked matrices and
matrices which were cross-linked only. Degradation was carried out with 200 units
collagenase/ml for 24 h at 37°C. Columns show the mean values, error bars represent the
corresponding standard deviations (n=5).
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3.3 Determination of free amino groups in the modified collagen
matrices
As discussed before, the modified collagen matrices are cross-linked between Hep-
COOH and NH2-collagen due to reactions induced by EDC/NHS. Due to the cross-
linking process, the number of free primary amino groups of collagen matrices will be
reduced whereas the reaction products of EDC/NHS will be washed out. Therefore the
number of free amino groups directly correlates with the degree of cross-linking.
Figure 18 shows the number of free amino groups per 1000 amino acids as a function
of the modification parameters. For the non-modified collagen matrix (H0E0) I
determined 36 free amino groups per 1000 amino acids, upon modification the number
gradually decreased to 34 in H1E0.5, 32 in H1E1, 28 in H1E2 and 21 in H1E4. The
results are in fairly good agreement with the results of the in vitro degradation
experiments. The number of 36 free amino groups in non-modified collagen matrices
nicely fits to the number of lysines and hydroxylysines present in collagen Type 1 from
bovine sources (Bubnis and Ofner, 1992). This means that only a small number of
lysines and hydroxylysines may be involved in the dehydrothermal treatment.
Figure 18   Free amino groups of collagen matrices modified according to parameters
specified in Materials and Methods. Free amino groups were determined with
trinitrobenzenesulfonic acid (TNBS). Columns show the mean values, error bars
represent the corresponding standard deviations (n=5).
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3.4 Determination of moisture uptake
Collagen is a porous hydrophilic material, which can bind large amounts of liquid.
Heparin is also hydrophilic and it was reported that after heparin immobilisation in the
collagen matrices, its water binding capacity will increase (Tsai et al., 2001). I
therefore investigated the moisture uptake of the modified collagen matrices. As
expected, the moisture uptake (Figure 19) increased with increasing EDC/NHS to
heparin ratios, thus with increasing additional cross-linking and increasing extents of
immobilized heparin. Hence the results correlate with the degree of cross-linking and
the extent of immobilized heparin which both reach a plateau with H1E2.
Figure 19  Moisture uptake of heparinized and cross-linked collagen matrices.
Columns show the mean values, error bars represent the corresponding standard
deviations (n=5).
In order to investigate whether different degrees of cross-linking lead to a change in
moisture uptake, I investigated the effect the EDC/NHS cross-linking in the absence of
heparin in the reaction solution. The results show that the moisture uptake increased
with increasing cross-linking degrees, leading to moisture uptake of 6.8 and 9.5 mg/mg
for H0E0.2 and H0E4 resp. (see Figure 20).
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Figure 20  Moisture uptake of collagen matrices which were cross-linked only.
Columns show the mean values, error bars represent the corresponding standard
deviations (n=5).
3.5 Correlation of heparin immobilisation and in vitro
degradation percentage among the modified collagen
matrices
The extent of heparin immobilisation increases with the increased of the ratio of
EDC/NHS to heparin, the in vitro degradation of the modified matrices, however,
decreased (Figure 21). The amount of immobilized heparin in H1E0.2 was less than
10 µg/mg collagen and its degradation percentage reached 69% which was nearly the
same as  that of H0E0, whereas, the amount of heparin in H1E2, H1E4 was more than
40 µg/mg collagen, but their degradation percentages were less than 10 % for H1E2
and less than 5% for H1E4, which means that with the high amount of heparin
immobilisation accompanied with lower degradation degree in vitro, the immobilised
heparin release willkeep a long time after implanting into the body.
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Figure 21 Relationship between the immobilized heparin and the in vitro degradation
of collagen matrices modified at varying heparin to EDC/NHS ratios (40 units
collagenase/ml of PBS at 37°C for 2 h) (n=5).
Oberviously, I showed that higher heparin to EDC/NHS ratios result in lower resistance
to in vitro degradation, whereas, the heparin immobilisation of such modification only
resulted in a bit less (Figure 9, 10). Furthermore, I analysed  the amount of heparin
immobilisation 33 µg/mg of H2E1, 40 µg/mg of H2E2, 38 µg/mg of H3E2, whose in
vitro degradation percentages are 20 %, 30 %, and 55 % respectively. As we know,
after modified collagen matrices degraded, the immobilised heparin and their binding
growth factors will release into the surrounding tissues. This results shows that a large
range of heparin and their binding growth factors release could be chosen with the
different ratio of heparin to EDC/NHS and EDC/NHS to heparin.
Furthermore, these analyses show that it might be possible to produce matrices which
bind the same amount of heparin, but are characterized by different degradation
behaviours (Figure 22).
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Figure 22  Comparison of the extent of the heparin immobilisation and the in vitro
degradation with of 40 units collagenase /1ml of PBS buffer, under 37°C for 2 h (n=5).´
3.6 Angiogenic potential
3.6.1 Angiogenic potential  determined by the chorioallantois
membrane assay
3.6.1.1 The macroscopic evaluation with CAM assay
After inculation of the specimen onto the chorioallantoic membrane for 7 days, the
macroscopic changes were observed for each collagen sample and the surrounding
Figure 23   Macroscopic evaluation of specimen implanted on chorioallantoic menbrane  of
chicken embryo for 7 days. Vessels grow towards the implantant in a spoke-like manner
(arrow head). About 80% of implantant are overgrown by granulomatous tissue of membrane
(arrow).
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chorioallantoic membrane are excised and mounted on a slide. Photographs of the
excisions are taken. Figure 23 shows a picture of an excised part of the chorioallantoic
membrane, the collagen implant (H0E0) is almost engulfed from the chorioallantoic
membrane and the vessels are clearly oriented in a spoke-like manner.
Table 2 compiles the characteristics investigated.  The data of 10 eggs of each
experimental group were used for calculatiion of the percentages. Death rates
represent of percentage of dead embryos during the whole incubation period. Area
reduction means the reduction of surface area of implants after contact. As for the
vessel form, spoke-like means that the vessels grow towards the implantant (see
Figure 23, arrow heads) and undirected means that the vessels grow without a such
direction. Finally, overgrowth by granulomatous tissue of the specimen represents the
part of the specimen engulfed by the surrounding  chorioallantoic menbrane (Figure
23, arrow) .
Table 2 Macroscopic evaluation of CAM assay experiments
Modification
parameters
Death
incidence
[%]
Area
reduction
[%]
Vessel structure [%]
Overgrowth by
granulomatious
tissue [%]
Control 20 - undirected  (100) - -
H0E0 20 50 undirected  (33,3) spoke-like  (66,7) 70
H0E0.2 20 30 undirected  (33,3) spoke-like  (66,7) 80
H0E0.5 10 20 undirected  (25) spoke-like  (75) 70
H0E1 10 10 undirected  (0) spoke-like  (100) 60
H0E2 25 5 undirected  (0) spoke-like  (100) 60
H1E0.2 20 40 undirected  (50) spoke-like  (50) 75
H1E0.5 15-20 30 undirected  (25) spoke-like  (75) 80
H1E1 20 15 undirected  (0) spoke-like  (100) 75
H1E2 20 10 undirected  (25) spoke-like  (75) 75
Control+VEGF 20 - undirected  (100) spoke-like  (0) -
H0E0+VEGF 20 50 undirected  (33) spoke-like  (67) 60
H1E0.2+VEGF 20 35 undirected  (25) spoke-like  (75) 75
H1E1+VEGF 15 20 undirected (25) spoke-like  (75) 75
H1E2+VEGF 20 10 undirected (0) spoke-like  (100) 75
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Regarding the death rates of the various modification parameters, we did not find the
obviously different from the death rates of the control group. The percentage of spoke-
like vessel organisation in the surrounding tissue  increases with increasing degrees of
cross-linking, heparin immobilisation and VEGF loading. The percentages of the
overgrowth by granulomatous tissue - by the chorioallantoic membrane - of modified
samples are not significantly different from the control group.
3.6.1.2 The microscopic evaluation with CAM assay
The angiogenic potential of an implant is now derived from the number of microvessels
in three defined areas in the vicinity of the implant. Vessels were counted as described
by Zwadlo-Klarwasser (Zwadlo-Klarwasser et al., 2001) and in Materials and Methods.
Figure 24 shows a microscopic photograph of the chorioallantoic membrane at a site
in close proximity of an implant, the rectangle restricts the area in which the
microvessels were counted.
Figure 24  Microscopic evaluation of angiogenic potential of collagen matrices by counting
mcirovessels in the chorioallantoic membrane of the chicken embryo (Magnification 22,5).
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3.6.1.3 Angiogenic effect of immobilized heparin as  determined by
the CAM assay
We first tested the angiogenic potential of collagen matrices modified with different
ratios of EDC/NHS and heparin. The modified specimen matrices were mounted on
the chorioallantoic membrane of the embryonated eggs under sterile conditions and
incubated for 7 days at 37°C. The results show that a higher ratio of EDC/NHS to
heparin increase the angiogenic potential. The number of the capillaries counted in the
CAM increased gradually from 58 (control) to 110 (H1E2) (Figure
Figure 25  Number of capillaries counted in the vicinity of the collagen matrices. The
increase of capillaries was obtained by subtracting the number of capillaries of the
control. Columns show the mean values, error bars represent the corresponding
standard deviations (n = 5).
As shown above, the amount of immobilized heparin increases with higher EDC/NHS
to heparin ratios (see Figure 9). Comparing the correlation of the amounts of heparin
immobilisation and the angiogenic potential of the same modification, it is obvious that
there is a trend of the effect of angiogenic potent and the amount of heparin
immobilisation as well. This suggests that the angiogenic potential of modified
matrices is caused by immobilised heparin (Figure 26).
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Figure 26 Correlation of the increase of capillaries of heparinized, cross-linked
collagen matrices with the amounts of immobilized heparin in these matrices. Results
are taken from Figures 10 and 24 respectively.
3.6.1.4 Angiogenic effect of EDC/NHS cross-linking as determined
by CAM assay
To further evaluate the heparin effect on angiogenesis observed in CAM assay, I
evaluate the possible angiogenic potential of the collagen matrices  modified with
EDC/NHS alone in the samples the modification procedures were the same as those
of heparin immobilisation, except heparin application.
In the CAM assays, I  showed that cross-linking of collagen matrices leads to a
substantially improved angiogenic potential and this effect becomes more evident with
increasing degrees of cross-linking. The number of the capillaries counted gradually
increases from 48 for the control group to 64 for H0E0 and 100 for H0E2 (Figure 27).
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Figure 27  Angiogenic effect of  collagen matrices which were cross-linked only.
Columns show the mean values, the error bars represent the corresponding standard
deviations (n = 5).
Considering that the increase of the angiogenic potential might be due solely to the
cross-linking effect, I  compared the angiogenic potential of collagen matrices which
were cross-linked in the absence of heparin (H0-series) with collagen matrices which
were both heparinized and cross-linked (H1-series). I  observe that upon comparison
of H1E0.2 to H0E0.2 and of H1E1 to H0E1, the differences are relatively small,
demonstrating that the effect on the angiogenic potential is mainly due to the cross-
linking effect and that the immobilized heparin only has a small additional influence
(Figure 28).
0
20
40
60
80
100
120
140
Control H0E0 H0E0,2 H0E0,5 H0E1 H0E2
Modification parameters
N
um
be
r o
f c
ap
ill
ar
ie
s
Number of capillaries
56
Figure 28   Correlation of the angiogenic effects of modified collagen matrices: H1Ex-
matrices were both heparinized and cross-linked, H0Ex-matrices were cross-linked
only. For comparison the corresponding amounts of immobilized heparin are also
shown. Columns show the mean values of the increases, the data on the heparin
immobilization were taken from  Figure 24, 26 and 10 resp. .
3.6.1.5 The angiogenic effect  of loading VEGF to heparinized and
non-heparinized collagen matrices as evaluated by the CAM
assay
As mentioned in the introduction, VEGF is a potent angiogenic growth factor
specifically acting on vascular endothelial cells and which is characterized by a high
affinity towards heparin. I  therefore modified collagen matrices by incorporation of
heparin within the matrices by covalent immobilisation. In a series of experiments I
evaluated the angiogenic effect of loading VEGF to heparinized and non-heparinized
collagen matrices by the CAM assay.
The results show that the number of capillaries increases as a result of the loading of
rhVEGF165 to both heparinized and non-heparinized collagen matrices. As compared
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to the increase of the number of capillaries of the control group loaded with 30 ng
VEGF (13,5), that of H1E0.2 with 30 ng VEGF reaches 36,8, that of H1E1 and H1E2
with VEGF reaches 67,6 and 63,6 respectively (Figure 29).
Figure 29  Angiogenic effects of loading VEGF to heparinized collagen matrices (30 ng
VEGF/collagen matrix). Columns show the mean values, error bars represent the
corresponding standard deviations (n=5). Numbers indicating the corresponding increases
were obtained by subtracting the number of capillaries of the control from each value.
To evaluate the angiogenic potential of all modification parameters, I  subsequently
investigated the following set of modified collagen matrices in a single CAM
experiment: 1. matrices modified by EDC/NHS cross-linking only, 2. matrices with
EDC/NHS cross-linking and heparin immobilisation, both in the presence and absence
of  VEGF.
The results of Figure 30 confirm that the number of increase of capillaries of H1E1
(70/40) in the presence and absence of VEGF preloading is more than those of  H0E0
(15/5) and H0E1(55/35). It could be clearly found from Figure 31 that the strongest
angiogenic potential was acquired in the modification of H1E1 with VEGF preloading.
Furthermore, the additional effect exerted by VEGF loaded in H1E1 was about 1,5 to2
times stronger compared to that with H0E1 and H0E0.
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Figure 30   Evaluation of the  angiogenic effect of loading of 100 ng rhVEGF165 to
non-modified (H0E0), heparinized and cross-linked matrices (H1E1), as well as
matrices which were cross-linked only (H0E1). Columns show the mean values, error
bars represent the corresponding standard deviations (n=5).
Figure 31  Additional angiogenic effects of loading of VEGF  to heparinized and non-
heparinized collagen matrices. The upper parts of the columns represent the additional
effect exerted by VEGF loading. Data are taken from Figure 30.
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3.6.2 Angiogenic effect of VEGF loading as determined by the
          hemoglobin content of explanted collagen  matrices
For the evaluation of the angiogenic effect of loading of rrVEGF165 to heparinized and
non-heparinized collagen matrices I  implanted these matrices subcutaneously on the
back of Lewis rats. Details of the procedures applied in these animal model
experiments are given in chapter 2 (Materials & Methods).
The macroscopic observations of the collagen specimen explanted after 15 days are
shown in Figure 31. The colour intensity of the explanted specimen increases with
increasing degrees of cross-linking. The loading with VEGF has in all cases an
additional angiogenic effect. The colour intensity of the collagen matrix H0E0 is low,
whereas the colour of H1E1 loaded with VEGF is dark red. The colour intensities of
the other modifications are intermediate.
Figure 31 Photographs of explanted collagen matrices after 15 days implantation.
Indicated specimen were loaded with 300 ng rrVEGF165
The angiogenic effect was investigated also by determining the hemoglobin content in
the explanted matrices. The hemoglobin content was determined after washing and
degrading the matrices with collagenase by difference VIS-spectroscopy at
wavelength around 410 nm (Soret band) using a calibration curve obtained from
sperm whale myoglobin. The calibration curve used is shown in Figure 32.
H0E0
H0E0 +
VEGF H0E1
H0E1+
VEGF
H1E1 +
VEGF
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Figure 32  Standard curve for hemoglobin determination
Figure 33  shows that the hemoglobin content of the explanted collagen matrices
increases with increased cross-linking and that the loading of rrVEGF165 has an
additional angiogenic effect. Thus the highest angiogenic effect is obtained with
collagen matrix H1E1 loaded with VEGF (Figure 33).
Figure 33 Hemoglobin content of  collagen matrices explanted after 15 days
implantation. Part of the matrices (as indicated) were loaded with 300 ng rrVEGF165
prior to implantation  in rats. Columns show mean values, error bars represent the
corresponding standard deviations (n=2).
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Figure 34 Angiogenic effects of loading 300 ng rrVEGF165 to heparinized and non-heparinized
collagen matrices. The upper parts of the columns represent the additional effect exerted by
VEGF loading. The angiogenic effects were evaluated by determination of the hemoglobin
content in the explanted matrices after 15 days implantation (n=2). Data are taken from Figure
33.
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4 Discussion
The final goal of tissue engineering is to develop engineered tissues which can replace
or regenerate the host tissues completely after implantation.  Therefore, it  is essential
for cells - either seeded or ingrown from the surrounding host tissues – to survive. The
formation of a functioning vascular network for the supply of oxygen and nutrients is an
important prerequisite. It is not surprising that the development of biomaterials with
enhanced angiogenic potential are of primary interest in tissue engineering (Nomi et
al., 2002).
Many ideas have been put forward to develop biomaterials with improved angiogenic
capabilities. One of these methods is to incorporate angiogenic growth factors into
biomaterials in order to release these growth factors in a sustained manner. Collagen
is of great interest as a biomaterial since it is biodegradable, biocompatible, non-toxic,
suitable for cell attachment and ingrowth.
Naturally, much attention has been directed towards the incorporation of angiogenic
growth factors into collagen matrices. Several approaches have been applied: in one
approach the growth factor TGF-ß was covalently linked to the collagen with a
homobifunctional cross-linking agent (Bentz et al., 1998), in another approach VEGF
was loaded in and released from microspheres (Peters et al., 1998). However, these
two methods will include the reaction chemicals into the biomaterials which may have
some influence on the host after implantation. Therefore, I  investigate the physical
binding of VEGF to collagen matrices in which heparin molecules were covalently
attached. Compared to the two methods mentioned above, at least three advantages
of our present approach could be concluded:
1 Heparin is immobilised into collagen matrices with the water soluble
cross-linking agent EDC/NHS which leads to a zero length bonding
that does not include inside the biomaterials after cross-linking and the
supplementary reagents and reactants can be washed out easily after
reaction.
2 After binding to heparin, VEGF may be protected from denaturing and
its  bioactivity may increase (Sommer and Rifkin, 1989).
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3 Collagen is a thrombogenic material which induces platelet adhesion
and aggregation, as well as activation of intrinsic blood coagulation.
Immobilized heparin may decrease the thrombogenic potential of
collagen and may be beneficial to vascular endothelial cells of the
surrounding tissue and may encourage them to migrate in.
A substantial number of characteristics of modified and non-modified collagen
matrices have been subject to our present investigation:
1 the amount of heparin immobilisation
2 in vitro degradation rate
3 the number of primary free amino groups
4 moisture uptake
5 the angiogenic potential of (non-)modified samples in the presence and
absence of VEGF.
4.1 The mechanism of the modification procedure
Several reports claim that the cross-linking agent EDC/NHS may be used to activate
the carboxyl acid groups of collagen to highly active succinimidylesters, which react
with free amino groups on neighbouring collagen fibrils, resulting in the cross-linking of
collagen. Heparin is an anionic linear polysaccharide consisting of two repeating
disaccharide units. It also has carboxyl groups in the two repeating disaccharide units.
Thus, EDC/NHS can also be used for activating the carboxyl groups of heparin.
Heparin is covalent linked to EDC first,  followed by EDC-activated carboxyl groups
which react with NHS-esters, which prevent the side reactions like hydrolysis of EDC
activated groups or an O-N-acyl shift. After activation of the carboxyl groups on the
heparin, dry collagen matrices are immersed into the reaction solution. The activated
carboxyl acid groups of heparin now react with free amino groups on the collagen
surface leading to „zero length“ covalent bond between the COOH-group on the
heparin and the NH2-group on the collagen (see Figure 2). Since  having a high
solubility in water, the reaction products of EDC/NHS are washed out easily, .
After immobilisation, the modified collagen matrices are washed extensively with
sodium chloride and distilled water to remove all the reaction products and non-
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immobilized heparin. In the procedure of Wissink et al. (Wissink, et al, 2001b), heparin
was immobilised to collagen matrices which were previously cross-linked. In our
procedure heparin is immobilised to collagen matrices which were not chemically
cross-linked. Additionally the cross-linking of the heparin and the additional cross-
linking of the collagen were performed in a one step procedure. Since the number of
primary free amino groups in non-cross-linked collagen is higher than in cross-linked
collagen ones, I think there should be more free amino groups of non-cross-linked
collagen available to react with activated carboxyl acid groups of heparin.
The next step will be to physically bind VEGF to heparinized collagen matrices. There
are reports  that bFGF binds to heparin immobilised in collagen films (Wissink et al.,
2001a). Therefore I  have chosen a reaction time of 90 minutes for binding VEGF to
heparin is at room temperature because our collagen matrices is much thicker (5 mm)
than that of film (20 µm). Figure 33 shows a schematic illustration of  the physical
binding of VEGF heparinized collagen matrices and of the additional cross-linking of
the collagen fibers.
Figure 33  Schematic representation of physical binding of angiogenic growth factors
to heparin covalently linked to collagen fibrils by cross-linking with EDC/NHS.
VEGF/bFGF
fibrillar
collagen
Heparin
EDC/NHS-Crosslinking
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4.2.  Immobilisation of heparin
4.2.1.  Optimal conditions for immobilisation
One of the objectives of the present investigation is to develop modified collagen
matrices which have the ability to physically bind a high amount  VEGF  and release it
in a controlled way.  Since VEGF binds with a high affinity to heparin, the binding
capacity directly correlates with the extent of heparin immobilisation. Thus our first
goal is the development modified the collagen matrices with incorporated high values
of heparin.
Heparin was reported to be successfully immobilised into collagen films with the cross-
linking agent EDC/NHS (Wissink et al., 2001b). This group used MES buffer with pH
5.6, the heparin carboxyl groups were activated from 5 to 30 minutes and the time
allocated for heparin immobilisation was 2 h. Taken their results as guide lines for our
experiments, I  decided to use MES buffer (pH 5.6) as reaction buffer and 10 minutes
for the time of heparin pre-activation. In order to achieve an increase of the heparin
immobilisation, I   first tested whether a reaction time of 2 h is sufficient for obtaining
optimal heparin immobilisation. I  determined the amount of heparin immobilisation
after reaction periods varying from 0.5 to 4 h. Our results show that a reaction time of
2 h is not sufficient for the maximal heparin immobilisation. The amount of immobilized
heparin reaches a maximal value at 4 h and does not increase any further (data not
shown). This difference between our results and those of Wissink et al. may be
explained by different sizes of the collagen matrices. Whereas I  use cubic specimen
(5*5*5 mm), they use collagen films with a thickness of 50 µlµl. Therefore, the reaction
agent might need more time to diffuse into the matrix.
As a next step I  investigated four different procedures for the immobilisation of
heparin. I  obtained the best results with procedure 1 in which is to preactivate
carboxyl acid groups of heparin  with EDC/NHS for 10 min, followed by reaction with
collagen matrix for additional 4 h. (Figure 8). This is not surprising because of the
principle of competition. In the case the carboxyl groups of heparin are activated first,
they will preferentially react with the free amino groups of collagen. Therefore,
procedure 1 results in the highest amount of immobilized heparin and the lowest
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resistance to collagenase degradation since less EDC/NHS are left to additionally
cross-link the collagen. As compared to procedure 1, procedures 2, 3 and 4 result in
lower amounts of immobilized heparin and a slightly higher resistance towards
collagenase degradation. The heparin immobilisation in procedure 3 is slightly lower
than that of procedure 2, I  guess that after the immersion of the specimen into the
heparin solution,  heparin will be distributed all over the matrix, thus the activation of
the carboxyl groups may interfere with the cross-linking of the collagen. Therefore, the
resistance to collagenase degradation is slightly  lower than that of procedure 2. If the
specimens are lyophilised after immersion into the activated heparin solution, the
disadvantage caused by the heparin distribution will be compensated for. Therefore,
the results of procedure 4 are similar to the results of procedure 2.
The washing procedure, as described by Wissink et al., takes about one week. I  tried
to reduce the time of the washing procedure. Collagen specimens which were
subjected to the washing procedure of Wissink et al. were compared with specimens
which were washed within two days. No differences were observed as evaluated from
the amount of immobilized heparin and from the death rate of the chicken embryos in
the CAM assay (See table 2). I  therefore decided to restrict the extensive washing
procedure to two days.
In summary, the optimal reaction procedure for cross-linking heparin to collagen is the
following: 1. carboxyl groups on the heparin are activated with EDC/NHS for 10
minutes, 2. dry collagen matrices are immersed and evacuated for 5 minutes to be
homogeneously equilibrated, 3. reaction period should be 4 h, 4. the heparinized
samples are washed extensively over a period of two days.
4.2.2 Methods to  determine the amount of immobilized heparin
The toluidine blue assay, applied for our experiment, was reported widely for
evaluation of the amount of immobilized heparin.  The results are stable and
reproducible. In principle I  adopted the procedures as published by Hinrichs et al.
(1997). The washing steps for removing the non-bound toluidine blue are essential for
obtaining reliable results.  Wissink et al. (Wissink, et al, 2001b) washed their collagen
specimen after complexation twice for 5 minutes with water. In our hands this
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procedure appeared to be not sufficient. Therefore I  washed the specimen with a
relatively large volume of distilled water (10 ml per sample) for about 16 h (overnight)
and changed the water 5 times. After this extensive washing procedure, virtually no
heparin is detected in collagen matrices H1E0. Therefore, I am convinced that all
physically absorbed heparin was washed out under the conditions used.
4.2.3 Extent of heparin immobilization as a function of varying
EDC/NHS to heparin and heparin to EDC/NHS ratios (w/w)
I first evaluated the heparin immobilisation with gradually increasing weight ratios of
EDC/NHS to heparin. Ratios were varied from 0 to 4 with intermediate steps at 0, 0.2,
0.5, 1, 2 and 3.  I  observed that up to a ratio of EDC/NHS to heparin of 2, higher ratios
of EDC/NHS to heparin result in higher the amounts of immobilised  heparin. The
results are in agreement with the reports of Wissink et al. (Wissink et al., 2001b). It
seems that by increasing the EDC/NHS-heparin ratio, more reactive N-
Hydroxysuccinimidylesters of EDC-activated carboxylic acid groups are introduced per
molecule  of heparin, which finally results in an increased heparin immobilisation. The
maximum level of heparin immobilisation in our experiments reaches 45 µg of heparin
per 1 mg of collagen, this was obtained at EDC concentrations of 2 mg per 500
microliter.  A further increase of the EDC/NHS to heparin ratio from 2 to 4 does not
lead to a further increase of the amount of heparin immobilisation. Apparently the
activation of all carboxyl groups of the heparin requires a certain amount of EDC/NHS.
This shows that the  reaction of EDC activated carboxyl groups of heparin reach a
saturation at the ratio of 2:1. Further increases of the ratio do not lead to higher
amounts of immobilized heparin. Hence the surplus EDC/NHS will activate carboxyl
groups of collagen, leading to an additional cross-linking of collagen instead.
 I expected that the increase of heparin concentrations would promote the
immobilisation of heparin. The weight ratio of heparin to EDC/NHS was investigated in
our experiment. Surprisingly this increase was undeveloped. A possible explanation is
that the higher concentrations of heparin may consume more EDC/NHS, therefore,
less surplus EDC/NHS for cross-linking. The deduce is confirmed by in vitro
degradation experiments which demonstrate that with higher heparin to EDC/NHS
ratios leads to a smaller resistance to collagenase degradation. In the previous
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experiment, the maximal amount of heparin immobilisation is achieved at ratios of
EDC/NHS to heparin 2:1.
In conclusion, the extent of the heparin immobilisation largely depends on the increase
of EDC/NHS to heparin ratio. Maximal immobilisation is achieved at ratios of 2:1,
higher ratios will not promote heparin immobilisation further.  Increased heparin to
EDC/NHS ratios, however, lead to lower levels of heparin immobilisation and a
concomittant decrease of the resistance versus collagenase degradation.
4.3 Evaluation of cross-linking of collagen matrices
Collagen is a degradable material and should stimulate the surrounding tissue to
regenerate. It is therefore important to control the degradation of modified collagen
matrices. Two methods are applied for evaluation the degradation degree in vitro. The
first is to determine the resistance of modified samples to bacterial collagenase which
is capable of cleaving peptide bonds within the triple helical structure and has a
specificity for the Pro-X-Gly-Y sequences, cleaving the peptide bond between X and
Gly. In our experiment the in vitro degradation was performed with collagenase from
Clostridium histolyticum. A gravimetrical method was used to determine the weight-
loss of treated collagen matrices. The second method determines the primary free
amino acid groups in the (non-)modified collagen matrices by using TNBS.  I  used the
procedure as described by Zeeman et al (Zeeman et al., 1999). I  introduced a number
of modifications due to the different size of our specimens. The reaction period was
changed from 2 to 16 h and the introduction of an  additional extraction of non-
complexed TNBS with ethylether. If the latter extraction step is  omitted as reported by
Zeeman et al. (Zeeman et al., 1999), the observed numbers of free amino groups are
far too high.
Our results of the in vitro degradation experiments with collagenase show that the
resistance towards degradation increases with  increasing EDC/NHS to heparin ratios
(w/w) (see Figure 11)  The relatively sharp drop between H1E0.2 and H1E1 was
surprising and might be explained as followed. The degradation percentage of H0E0
and H1E0.2 are almost identical, I  conclude that 0.2-0.3 mg of EDC/NHS are
consumed for  activating all carboxyl groups present in 1 mg heparin. This figure nicely
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corresponds to the amount of EDC which I  calculated to be required for activating all
carboxyl groups. For this calculation I  assume that the average molecular mass of
heparin is 12500 Da and that the average number of carboxyl groups is 18,75 per
molecule. On the basis of these assumptions I  calculate that 0,3 mg of EDC are
consumed for activating all the carboxyl functions. The presence of 0.5 mg EDC/NHS
in the activation mixture of H1E0.5 leaves about 0.2-0,3 mg of EDC for the additional
cross-linking of the collagen. This may explain the relatively sharp drop observed
between the modification parameters H1E0.2 and H1E1.
The activation of more heparin with the same concentration of EDC, however, leads to
less cross-linking since more EDC is consumed for activating the heparin. This implies
that heparin to EDC/NHS ratios of  4:1 will result in almost no EDC/NHS left for
additional cross-linking of the collagen, although a similar amount of heparin will be
immobilised.  As the sensitive cross-linking effect is influenced by the ratio of
EDC/NHS to heparin, I  think it is necessary to compare the net cross-linking effect of
EDC/NHS to the results above.
From Figure 14,  I  conclude that even at the modification parameters H0E0.2 some
degree of cross-linking is observed. The degradation percentage of H0E0.2 ranges
between H1E0.5 and H1E0.75. This fact may be explained by assuming that about 0.2
mg of EDC/NHS are available for cross-linking with H1E0.5 and H1E0.75.  Thus  the
apparent differences could be produced among the modified sample of H1E0.2,
H1E0.5 and H1E1.
The extent of cross-linking can also be evaluated by the method of determination of
the number of primary free amino acid groups in the modified collagen matrices (Olde
Damink et al., 1996). As explained before, the heparin immobilisation and the
additional cross-linking occur through the linkage of carboxyl groups of heparin or
collagen to adjacent free amino groups in the polypeptide chains of collagen.  From
Figure19, we can see that there is a gradual decrease of the number of free amino
groups. At first sight it may be surprising that the relatively sharp drop in the
degradation percentage between the modification parameters is not observed.  Since
the  heparin present in the activation mixture initially will consume about 0.2 mg of
EDC/NHS no EDC will be left for additional cross-linking. This explains why there is
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almost no change in both the degradation percentage and the number of free amino
groups in collagen matrices prepared according to the modification parameters H1E0
(36 per 1000 amino acids) and H1E0.2 (36 per 1000 amino acids).  With increasing
EDC/NHS concentrations at the constant concentration of 1 mg heparin per 500
microliter, I  observe a slow down of the degradation percentage whereas there is a
further decrease of the number of free amino groups. Apparently the increase of the
EDC/NHS concentration in excess of 1 mg/500 microliter does not lead to a further
shrinkage of the collagen fibrils, it does, however, lead to a continuation of formation of
intrachenar cross-link bonds. This may explain why the degradation percentage, and
the amount of immobilized heparin and the moisture uptake do not change anymore.
In summary, by using the cross-linking agent EDC/NHS, heparin is covalently bound to
the polypeptides chains of collagen and the excess reagent additionally cross-links the
collagen. The degree of cross-linking of modified collagen matrices increases with
increasing EDC/NHS to heparin ratios. The addition of more heparin to the reaction
solution leads to less incorporation of heparin as well as less additional cross-linking:
whereas the amount of immobilized heparin is reduced to a small extent, the impact on
the degradation behaviour is substantial. This means that I am able to produce a wide
range of modified collagen matrices incorporating various amounts of heparin and
exhibiting different in vitro degradation behaviours. For example, if an immobilisation of
35-40 µg heparin/mg collagen is required, I  have the option of choosing the following
different degradation performances: after a treatment with 40 units collagenase/1ml for
2 h 10% of H1E2, 15% of H2E2, 25% of H2E1, 60% of H3E2 and 65% of H4E2 are
degraded (see Figure 23).
 Since the extent of physical binding of VEGF may correlate with the amounts of
immobilized heparin, the VEGF release may also correlate with the in vitro and in vivo
degradation. I am thus able to control a wide range of VEGF binding and release
behaviours which will be of great help for the development of suitably modified
collagen matrices with enhanced angiogenic capabilities.
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4.4 Moisture uptake
In general, the moisture uptake or the hydrophilicity of collagenous materials
decreases with increasing degrees of  cross-linking (Weadock et al., 1995). In our
case, however, the moisture uptake of cross-linked collagen matrices shows
increased water binding as cross-linking increased (Figure 20, 21). I  postulate that
this observation may be due to the modification of the pore structure in the cross-
linked collagen matrices. In the absence of additional cross-linking, the degree of
cross-links is relatively low and therefore the non-modified collagen matrices have a
limited stability. Wet non-modified matrices are easily collapsed after „blotting“ them on
a piece of filter paper.
In fact, it was found in cell culture experiments  (Marth Markowicz, unpublished) that
the non-cross-linked matrices have a higher tendency to collapse. It has been reported
that resilience of cross-linked collagen matrices are much better than the non-cross-
linked ones (Chvapil, 1977). Comparing the matrices which were cross-linked in the
absence of heparin (H0Ex-series) to the matrices which were both heparinized and
cross-linked, the latter take up more moisture.  Heparin contains a variety of
hydrophilic groups such as R–O-, R-OH, R-COO-, R-NH-SO3 and R-O-SO3. They may
form hydrogen bonds with water molecules, making the heparinized collagen matrices
more hydrophilic than their non-heparinized counterparts. These results are in
agreement with data reported by Tsai et al., who immobilised heparin to collagen with
naturally occurring cross-linking agent genipin (Tsai et al., 2001).
It was also reported that increased grafting of hydrophilic groups induces a decrease
of fibrinogen adsorption and an increase of albumin adsorption (Papadimitriou et al.,
2000). Fibrinogen is known to be capable of mediating platelet aggregation and
adhesion via interaction with platelet receptors such as GP Ilb / IIIa and platelets do
not specifically interact with albumin or adhere to albumin-coated surfaces (Amiji and
Park, 1993).  In addition, it was also reported that the high moisture uptake of sponge-
like matrices seems to be dependent on the porosity of the structure (Patel and Amiji,
1996).  As far as our experiments are concerned, I  find that the cross-linked and
heparinized samples are more moisture uptake than the non-modified specimen.
Highly hydrophilic matrices, should allow for a more homogeneous seeding of the cells
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and a better ingrowth. More  hydrophobic matrices will make it more difficult to deliver
the cells from the surrounding tissues inside uniformly throughout the matrices (Freed
et al., 1993). The cross-linked and heparinized samples with high moisture uptake are
more stable compared to the untreated ones and therefore may be beneficial for
maintaining the desired shape while reserving sufficient free space for formation of
new tissue via cell proliferation and extracellular matrix secretion. In addition, it was
found that the increased moisture uptake capacity may beneficially influence tissue
remodelling by promoting open matrix structures (Cha et al., 1991).  Therefore, I
consider that the moisture uptake in modifying matrices represents an important factor
for influencing the angiogenic potential.
4.5 Evaluation of the angiogenic potential of modified collagen
matrices
As outlined earlier the main objective of this investigation is to deliver a contribution to
the development of collagen matrices with enhanced angiogenesis for a better oxygen
and nutrient supply. The angiogenic potential was evaluated with two different in vivo
assays: exposure of collagen matrices to the chorioallantoic membrane of the chicken
embryo (CAM assay) and subcutaneous implantation on the back of rats.
4.5.1 Angiogenic effects determined with the CAM assay
4.5.1.1 Angiogenic effect of cross-linking collagen matrices
I  found  that cross-linked collagen matrices promote the angiogenic potential in vivo.
With higher degrees of cross-linking, the stronger angiogenic potential resulted (Figure
26). At the present time it is difficult for us to fully explain this phenomenon. In a
collaborative effort, coworkers were able to show that a similar effect is observed when
vascular endothelial cells are exposed to the modified collagen matrices in vitro (Marth
Markowicz, unpublished) . I  may, however, postulate that the positive angiogenic
effect is due to the lower antigenicity of the cross-linked samples (Furthmayr and
Timpl, 1976) and thus will result in less foreign body reaction, which in general creates
a layer of non-vascularized structures that encapsulate the implants and hinder the
ingrowth of surrounding cells and vessels. In addition, the cross-linked matrices have
an improved structural stability, preventing them from collapsing, which may be
beneficial for surrounding vascular endothelial cells migrating in. I  furthermore
73
envision that the higher hydrophilicity of the cross-linked samples will allow for a more
tissue liquid to flow inside the samples homogeneously  and thus should be easier for
the surrounding cells migrating inside.
It is true that compared to the control experiments (no matrices being present on the
chorioallantoic membrane), the non-modified collagen matrices (H0E0) have some
angiogenic potential in vivo, though the effect is much weaker than the modified ones
(Figure 24).  I  think this is because of the inflammatory response due to the larger
antigenicity of non-modified collagen matrices. Upon implantation of the samples,
inflammatory cells will gather around and produce angiogenic growth factors such as
bFGF, PDGF which in turn stimulate angiogenesis. Therefore, I  think that the effect on
the angiogenic potential of non-modified samples is different from that of modified
ones which decrease the antigenicity and thus inflammatory response in vivo.
Therefore, it is of interest to investigate the mechanisms which determine the
angiogenic potential of cross-linked collagen matrices in the future.
4.5.1.2 Angiogenic effect of immobilizing heparin in collagen
matrices
In our experiment, I  find that the angiogenic effect of heparinized cross-linked
matrices becomes gradually stronger with the increased amount of heparin
immobilisation. Our results shown in Figure 25  suggest that the angiogenic potential
as expressed as the increase of the number of capillaries correlates with the amount
of immobilized heparin in the specimen. In order to test this hypothesis I  also
investigated the angiogenic effect of cross-linking collagen matrices in the absence of
heparin.
Considering that cross-linked collagen matrices can also be angiogenic potential, I
compared the results of angiogenic potential by cross-linking alone without heparin
immobilization (H0-series), heparin immobilization with cross-linking (H1-series) , and
the amount of heparin immobilsation  (µg heparin/ mg collagen ).  I   found that the
increased number of capillaries correlates more with the amount of cross-linking than
the degree of heparin immobilisation. From Figure 27, it seems to be concluded that
heparin has almost no angiogenic effect in chorioallantoic membrane experiments.
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But taking into account the results of the in vitro degradation experiments showing
that the cross-linking extent of the H0-series is quite higher than that of H1-series (see
Figures 15 and 16), I  observe that the degradation behaviour of H0E0.2 is similar to
that of H1E1. If I  compare, the angiogenic potential of matrices H0E0.2 with H1E1, the
extent of cross-linking  are similar, I  conclude that the amount of immobilized heparin
may have a small angiogenic effect (see Figure 28).  Our results therefore partly
support reports of van Wachem et al., who  found that the immobilisation of heparin in
collagen matrices leads to an increased vascularization when implanted in rats (van
Wachem et al., 2001). They explained this observation by postulating that the
heparinized collagen matrices trap heparin binding growth factors from the
surrounding tissue, which results in local induction of capillary vessel formation
(Meddahi et al., 1994).
In our experiments, the increase in the amounts of immobilized heparin is always
accompanied by a concomitant additional cross-linking of the collagen matrices. This
complicates the investigation of the angiogenic effect of immobilized heparin. I am
currently changing the modification procedure in order to be able to segregate the two
effects.
In summary, the modification procedure which incorporates heparin collagen matrices
exerts an important angiogenic effect in vivo. The effect is most likely due to the
additional cross-linking. The immobilised heparin may have a small additional effect. A
different modification procedure should make it possible to better discriminate between
the two effects.
4.5.1.3 Angiogenic effect of loading VEGF to heparinized collagen
matrices
As mentioned in 1.5.2, VEGF is a mitogen specific to vascular endothelial cells, as well
as a potent stimulator of angiogenesis in vivo.  I  therefore added VEGF to heparinized
and non-heparinized collagen matrices and investigated the angiogenic effect by using
the chorioallantoic membrane assay. As a first result I  observed that the addition of
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increasing amounts of VEGF (30 – 300ng) to the collagen matrices prior to the
application on the chorioallantoic membrane, does not lead to an increase of the
number of capillaries. Apparently the addition of 30 ng VEGF is already sufficient for
provoking a maximal effect. It was reported that an overdose of VEGF may lead to
malformation and nonfunctional capillaries (Springer et al., 1998), I , however, did not
observe such a development upon addition of 300 ng of VEGF. This may be due to the
procedure with which I  applied VEGF on the CAM assay.
In our experiments, different amounts of VEGF were loaded to non-modified collagen
matrices and then mounted on the chorioallantoic membrane for an incubation period
of 7 days. I  conclude that most of the added VEGF will diffuse out quickly after
implantation and may be then denatured rapidly due to the very short in vivo half life
time. Therefore, the high VEGF loading does not necessarily lead to a corresponding
increase of the angiogenic potential and neither results in deformed and nonfunctional
capillaries.
In summary, it may be concluded from these experiments that even very small
amounts of VEGF (30 ng) apparently produce substantial angiogenic responses in
vivo. Therefore, it is necessary to preload VEGF on the modified samples to acquire
sustained release. I  choose 30ng and 100ng of VEGF for further experiments.
Previously, preloading of EDC/NHS cross-linked collagen matrices with and without
heparin immobilisation with hVEGF165 was applied to cell culture assay and resulted
in the improvement of the proliferation of hUVECs in our laboratory cooperated by
Marth Markowicz . In this study, I  further evaluated the angiogenic potential of
proloading VEGF to (non-)modified samples and compared to the effects of none
VEGF preloading.
From the macroscopic observation, I  learned that the  percentage of spoke-like vessel
structure directed towards the implants, increases  when collagen matrices  H0E1 and
H1E1 are loaded with VEGF. I  thus conclude, that VEGF induces a directed vessel
growth towards the implants .
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The loading of VEGF to heparinized matrices results in a substantially angiogenic
effect compared to the  loading of VEGF to non-heparinized collagen matrices. (see
Figure 30).  The maximal response was observed when H1E1 matrices were loaded
with VEGF. Matrices with higher amounts of immobilized heparin did not lead to
stronger angiogenic effects. Apparently the loading of VEGF to heparinized matrices
leads – when in contact with the chorioallantoic membrane – to a more slowly and
sustained release provoking the observed angiogenic effect. Comparing of the results
in the H0E1 preloading with VEGF to those of H1E1 preloading with VEGF shows that
angiogenic potential is stronger in H1E1 preloading. It was reported that the physical
binding of VEGF to the immobilized heparin may promote their bioactivity and protect
them from denaturation in vivo (Sommer and Rifkin, 1989).
4.5.2 Angiogenic affect as determined by subcutaneous implantation in
rats
From the results of the hemoglobin content determination in explanted specimen, I
conclude that the H1E1 matrices loaded with 300 ng VEGF showed the largest
angiogenic effect. In our view, the hemoglobin content of the explants correlates with
the extent of newly formed vessels within the implants. This observation may be more
objective as compared to the counting of capillaries in the CAM-assay since it
represents the total amount of blood flow within the collagen matrices.
Collagen matrices, which were cross-linked only (H0E1), show - as observed by the
increase of the hemoglobin content - a substantially higher angiogenic potential  . I
deduce that this effect may be due to i) the larger pore size, ii) the more stable and
rigid structure and iii) the increase in hydrophilicity. Loading of 300 ng VEGF to these
matrices only leads to a relatively small increase of the angiogenic potential. This
effect may be explained by the fact that VEGF cannot physically bind to the cross-
linked collagen and thus rapidly diffuses into the surrounding tissue.
The collagen matrices which were both heparinized and cross-linked (H1E1)
demonstrate the highest angiogenic effects in the chorioallantoic assay both loaded or
non-loaded with VEGF. Matrices (H1E1) loaded with VEGF show the highest
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angiogenic effect. These results were confirmed by the colour intensity of the collagen
specimen explanted after 15 days. A clear cut increase in the colour intensity is
observed in the following order: H0E0, H0E1 and H1E1. In all cases the intensity of
the colour increases when the matrices were loaded with 300 ng VEGF prior to the
implantation. (see Figure 31). This means that the vascularization was maximal inside
H1E1 loaded with VEGF, the lowest degree of vascularization was observed with the
H0E0 specimen in the absence of VEGF.
The general conclusion then is that the loading of VEGF to heparinized collagen
matrices results in the highest angiogenic effect, this observation may be due to a
slow and sustained release of VEGF and a promotion of the bioactivity in vivo.
4.6 Conclusions
4.6.1 Characteristics of modified collagen matrices
(1).  Heparin was covalently incorporated into collagen with the cross-linking agents
EDC/NHS. The extent of heparin immobilization increases with increasing  EDC/NHS
concentrations and EDC/NHS to heparin ratios.
(2). The in vitro degradation also strongly depends on the EDC/NHS concentrations
and EDC/NHS to heparin ratios. Higher EDC/NHS concentrations and EDC/NHS to
heparin ratios lead to lower in vitro degradation rates. The results are confirmed by
determination of the free amino groups in the modified collagen matrices.
(3). The moisture uptake of modified collagen matrices increases with increasing
cross-linking of collagen and the extent of heparin immobilisation.
4.6.2 Angiogenic potential
1. The modification of collagen matrices with EDC/NHS generally leads to an increase
of the angiogenic potential. The cross-linking apparently has the most important effect,
the additional effect of the heparin incorporation is relatively small.
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 2. The loading of VEGF to the modified matrices results in an additional positive effect
on the angiogenesis. The largest additional effect was observed with VEGF loading to
heparinized matrices.
3. The loading of increasing amounts of VEGF to non-modified collagen matrices
(H0E0) does not lead to an increased number of capillaries.
4. The angiogenic potential as determined by the hemoglobin content of explanted
matrices increases with increasing cross-linking. The loading of VEGF has an
additional effect on the angiogenesis, again the largest additional effect was observed
with the heparinized matrices.
4.7 Future prospects
The development of a tissue substitute that can be used by the plastic surgeons and
other specialists is our main goal. Such tissue substitutes should be able to mediate
angiogenic responses in vivo and thus help to enhance cell survival and tissue
ingrowth. Ultimately the tissue substitute should be replaced by regenerated,
completely natural tissue.
 Based on the results obtained in the present investigation, the following topics further
should be investigated in the future.
1.  The binding of VEGF to modified collagen matrices as well as its release should
be evaluated in more detail by ELISA methods, or if necessary by radioactive
labeling of VEGF. It is necessary to better understand the correlation of the
release rates and the angiogenic effects in vitro and in vivo.
2. Since the sterilisation procedures may change the characteristics of modified
matrices and as a consequence the angiogenic potential in vitro and in vivo, it is
of interest to investigate the effects of the various sterilisation procedures.
3. I  evaluated the angiogenic potential by means of the chorioallantoic assay over a
period of 7 days. At the end of this period, most of the modified samples are not
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degraded, which means that there may still be some VEGF left and their effects
are not being evaluated yet. Therefore, longer evaluation periods may be
considered in the future.
4. I  observed that collagen matrices which were cross-linked only show an
increased angiogenic potential in vitro and in vivo, which means that the change
of pore structure may be a factor of importance for modulating  angiogenesis.
Therefore, I  think the porous structure of the various modified collagen matrices
should be evaluated by electron microscopy in order to better understand the
correlation between the structural changes and their angiogenic effects.
5. Additional animal experiments should be performed in order to quantify the
vessel ingrowth into the modified matrices. It may furthermore be  interesting to
evaluate the degradation behaviour of modified collagen matrices in vivo in
animal model experiments. If possible, I  think the amount of newly formed
collagen inside the matrices should be evaluated in the future. The new formed
collagen inside matrices means that the ability for such matrices to supply for the
survival of tissues ingrowth from surrounding.
6. Finally, the mechanics behind the changes of the angiogenic potential of modified
matrices should be investigated. One approach would be to investigate which
endothelial cell genes are switched on upon contact of these cells with modified
matrices  by using RT-PCR.
80
5 Summary
Introduction
Tissue engineering has been recognized as a viable concept for repair of tissue
defects. Ideally engineered tissues should be non-toxic, biocompatible, biodegradable
and angiogenic. The enhancement of the angiogenic capabilities is still a challenge to
us. Collagen is one of the major components of natural extracellular matrices and is
characterized by a high biocompatibility and a biodegradation without toxic byproducts.
Heparin, a well-known and time-honored antithrombotic drug, was also found to
regulate angiogenesis. Further, it has high affinity to angiogenic growth factors, such
as bFGF and VEGF. Based on these knowledge, collagen matrices were modified by
incorporation of different amounts of heparin and by cross-linking with EDC/NHS. A
variety of collagen matrices were produced according to a restricted number of
modification parameters. These matrices were characterized biochemically and
physicochemically. Finally their angiogenic potential were evaluated by exposure to
the chorioallantoic membrane of the chicken embryo and by subcutaneous
implantation in rats.
Methods
Collagen matrices, kindly provided by Dr. Suwelack Skin & Health Care AG,
Billerbeck, Germany, were cut into cubes of either 5*5*5 mm (3,8-4,2 mg) or cylinders
of 10 mm in diamter and 2 mm in thickness (3,8-4,2 mg).  Heparin was covalently
incorporated with EDC/NHS. Initially carboxylic acid groups of the heparin are
activated with  EDC/NHS at fixed EDC to NHS weight ratios of 1 to 0,6. The weight
ratios of EDC/NHS to heparin (w/w) varied from 0.2 to 4 and vice versa. After
activation, collagen specimen were immersed in the activation solution and incubated
for 4h to immobilise heparin and washed extensively subsequently. Samples were
frozen, lyophilized and stored at room temperature for further characterization:
determination of immobilised heparin (toluidine blue assay), free amino groups (TNBS
assay), degradation behavior (in vitro degradation with collagenase) and  moisture
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uptake.  VEGF loading was performed under sterile conditions, depending on the
application different amounts of VEGF were loaded.
Angiogenic effects were evaluated by exposure of the modified collagen matrices to
the chicken embryo chorioallantoic membrane (CAM assay) and subcutaneous rat
tissue. The number of capillaries in the chorioallantoic membrane were counted, the
macroscopic responses provoked by the contact with modified matrices were
evaluated. In the animal model experiments the angiogenic potential were deduced
from the hemoglobin contents in the explants.
Results
1 Characterisation of heparinized matrices
1.1 The extent of immobilized heparin and the moisture uptake increase with
increasing EDC/NHS to heparin weight ratios (w/w). The resistance to collagenase
degradation and the number free amino groups progressively decrease. Increase of
heparin to EDC/NHS ratios did not result in higher extents of immobilized heparin, but
in a sharp decrease of the resistance towards  degradation.
1.2 The moisture uptake of modified collagen matrices increases both with the
extent of immobilized heparin and the degree of cross-linking.
2 Angiogenic potential
2.1 Vessels show a spoke-like structure growing towards the modified matrices. The
higher the EDC/NHS to heparin weight ratio, the slower the degradation degree of the
matrices, which is in accordance with the in vitro collagenase assay.
2.2 The increased number of capillaries in CAM were observed with heparinised
collagen matrices and with collagen matrices which were cross-linked only.
2.3 No significant differences of the death rates of embryos were observed between
the control group of and the groups of non-modified and modified collagen matrices.
2.4 Loading of VEGF to heparinized matrices results in a strong promotion of
angiogenic potential in comparison with loading the same amount of VEGF to non-
modified and non-heparinized matrices.
2.5 Heparinized matrices loaded with VEGF had the highest angiogenic potential as
deduced from the hemoglobin washed out from these explants.
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Conclusions
1
In the present study I developed a procedure by which heparin is covalently
incorporated into collagen matrices. Modified collagen matrices are characterized by a
controllable biodegradability, heparin immobilisation and an improved moisture uptake.
They are furthermore non-toxic, have high affinities towards the angiogenic growth
factor VEGF and may represent biomaterials meeting specific requirements of tissue
engineering.
2
Modified matrices are characterized by substantially enhanced angiogenic capabilities
as evaluated from in vivo experiments. This increase apparently results from changes
in the microstructure of the collagenous matrix and from a sustained release of VEGF
from a VEGF-pool physically immobilized to covalently incorporated heparin.
3
These modifications may be of prime importance for future developments in the field of
skin substitutes, in which the rate of vascularization is essential for the survival of
seeded autologous or stem cells.
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7  Abbreviations
bFGF Basic Fibroblast Growth Factor
CAM Chorioallantoic Membrane
DHT Dehydrothermal Treatment
EC Endothelial Cell
ECM Extracellular Matrix
EDC N-(3-Dimethylaminopropyl)-N’-Ethylcarbodiimide
EDTA Ethylendiamin-Tetraacetate
EGF Epidermal Growth Factor
ELISA Enzyme-linked Immunosorbent Assay
FBR Foreign Body Reaction
Flt-1 Fas-Like Tyrosine Kinase-1
GA Glutaraldehyde
GAGs Glycosaminoglycans
Hb Hemoglobin
Hep-COOH Carboxyl Groups of Heparin
HUVEC Human Umbilic Vascular Endothelial Cell
KDR Kinase insert Domain-containing Receptor
MES 2-Morpholinoethane Sulfonic Acid
NHS N-hydroxysuccinimide
NMR Nuclear Magnetic Resonance
OD Optical Density
PBS Phosphate Buffer Solution
PDGF Platelet-Derived Growth Factor
PEG Poly Ethylene Glycol
rhVEGF165 Recombinant Human Vascular Endothelial Growth Factor (splice
variant with 165 amino acids)
SD Standard Deviation
SS Succinimidyl Succinate
TGF Transforming Growth Factor
TNBS Trinitrobenzenesulfonic Acid
VEGF Vascular Endothelial Growth Factor
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